Supporting Information for

Palladium-Catalyzed β-Mesylation of Simple Amide via Primary sp³C–H Activation

Ren Zhao, Wenjun Lu*

Department of Chemistry, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai 200240, People's Republic of China

Table of Contents

I. General Information	S-1
II. Experimental Section	S-2
1. Typical procedures	S-2
2. Screening the reaction conditions for β -mesylation	S-3
3. Screening the reaction conditions for β -fluoramides	S-6
4. Screening the reaction conditions for β -lactams	S-7
III. Preparations and Characterization of Compounds and NMR Spectra	S-8
1. Preparations and Characterization of Compounds	S-8
2. NMR Spectra	S-4 1

I. General Information

NMR spectra were obtained on a Varian Mercury 400 plus instrument and Bruker AMX-400 instrument (400 MHz for ¹H, and 100 MHz for ¹³C). ¹⁹F NMR spectra were recorded on Bruker AMX-400 instrument (376 MHz). HRMS data were recorded on ACQUITYTM UPLC & Q-TOF MS Premier. Melting points were obtained on an INESA SGW X-4 melting point apparatus.


All reagents were from commercial sources. Solvents were distilled before use. Flash

Chromatography was performed on silica gel (200-300 mesh).

II. Experimental Section

1. Typical procedures

(1) A typical procedure of preparation of amide substrates (*N*-(4-nitrobenzyl)pivalamide) (1a)



To a stirring solution of (4-nitrophenyl)methanamine hydrochloride (5.0 g, 26.5 mmol), Et₃N (6.7 g, 66.3 mmol) in DCM (50 mL), was added trimethylacetylchloride (PivCl) (3.8 g, 31.8 mmol) at 0 °C (ice/water bath). The reaction mixture was allowed to warm to room temperature, and stirred at rt overnight. After that, the reaction mixture was quenched with water (100 mL), and extracted with DCM (10 mL*3), washed with aq.K₂CO₃, brine, and dried over MgSO₄. Then, the combined extracts were concentrated and recrystallization from n-hexane/EtOAc (3:1, v/v) mixture to afford *N*-(4-nitrobenzyl)pivalamide (**1a**) (light yellow solid) (5.9 g, yield: 94%).

(2) A typical procedure of β -mesylation of amides


(2,2-dimethyl-3-((4-nitrobenzyl)amino)-3-oxopropyl methanesulfonate) (2a)

$$O_{2}N \xrightarrow{O} H + Ms_{2}O \xrightarrow{Cat. Pd(OAc)_{2}} CF_{3}CH_{2}OH \xrightarrow{O} H \xrightarrow{O} OMs$$

The mixture of *N*-(4-nitrobenzyl)pivalamide (**1a**) (236 mg, 1.0 mmol), Pd(OAc)₂ (4.4 mg, 0.02 mmol, 2 mol %), K₂S₂O₈ (108 mg, 0.4 mmol) in TFE (800 mg, 8 mmol) were heated at 80 °C for 2 hours (oil bath). Then another batch of Pd(OAc)₂ (18 mg, 0.08 mmol, 8 mol %), K₂S₂O₈ (432 mg, 1.6 mmol) was added to the mixture and reacted at this temperature for another 22 hours. After that, the reaction mixture was added CH₂Br₂ (90 mg, 0.50 mmol) as internal standard and detected by ¹H NMR analysis (yield: 82%). The reaction mixture was transferred into a 50 mL round-bottom flask and the solvent was evaporated. The desired β -mesylated amide (**2a**) was isolated by flash column chromatography on silica gel using n-hexane/ethyl acetate (2:1, v/v) as eluant, slurry product (247 mg, 75%) recrysalized from (PE/EtOAc), to give a light yellow solid (200 mg, 61%).

(3) A typical procedure of β -fluoride of amides


(3-fluoro-2,2-dimethyl-N-(4-nitrobenzyl)propanamide) (3a)



The above mesylation reaction mixture (from substrate, 1 mmol) (without purification)

was cooled to room temperature and filtered through celite. The cake was washed with EtOAc (10 mL*3) and the combined filtrate was evaporated under reduced pressure. The crude β -mesylated amide (**2a**) was added TFE (1 mL), and KF (330 mg, 4.5 mmol). The mixture was heated to 110 °C and stirred for 28 hours to give the β -fluoroamide product (**3a**). The reaction mixture was filtered through celite, washed with EtOAc (10 mL*3) and the combined filtrate was evaporated under reduced pressure. The crude mixture was detected by ¹H NMR analysis (yield: 74%). Then the desired β - fluoride amide (**3a**) was purified by flash column chromatography on silica gel using n-hexane/ethyl acetate (5:1, v/v) as eluant, to give a light yellow solid (165 mg, 65%).

(4) A typical procedure of β-lactam (3,3-dimethyl-1-(4-nitrobenzyl)azetidin-2-one) (4a)



The crude β -mesylated amide (**2a**) (from substrate, 1.0 mmol) was dissolved in CH₃CN (1 mL), then K₂CO₃ (276 mg, 2.0 mmol) was added. The mixture was heated to 80 °C and stirred for 26 hours to give the β -lactam product (**4a**). The reaction mixture was detected by ¹H NMR analysis (yield: 73%). Then the desired β -fluoride amide (**4a**) was isolated by flash column chromatography on silica gel using n-hexane/ethyl acetate (5:1, v/v) as eluant, to give a light yellow solid (150 mg, 64%).

2. Screening the reaction conditions for β -mesylation products




Table S-1 Effects of solvents

Entry	Solvent	Yield (%)
1	EA	13
2	CH ₃ CN	0
3	DMF	0
4	DCE	36
5	THF	trace

6	Dioxane	0
7	DCM	66
8	CHCl ₃	56
9	TFE	76

^a Yields based on substrate and detected by ¹H NMR analysis using CH₂Br₂ as internal standard. Conditions: **1a** (0.1 mmol), Pd(OAc)₂ (0.01 mmol), K₂S₂O₈ (0.2 mmol), Ms₂O (0.07 mmol), solvent (0.3 mL), 80 °C, 24 h.

Entry	Catalyst	Oxidant	Yield (%)
1	Pd(OAc) ₂	$K_2S_2O_8$	74
2	Pd(PPh ₃) ₄	$K_2S_2O_8$	38
3	Pd(PPh ₃) ₂ Cl ₂	$K_2S_2O_8$	25
4	Pd(TFA) ₂	$K_2S_2O_8$	60
5	PdCl ₂	$K_2S_2O_8$	0
6	Cu(OAc) ₂	$K_2S_2O_8$	0
7	Co(OAc) ₂ ·4H ₂ O	$K_2S_2O_8$	0
8	PtCl ₂	$K_2S_2O_8$	0
9	Pd(OAc) ₂	Oxone (1.25 equiv)	36
10	Pd(OAc) ₂	Oxone (2.5 equiv)	40
11	Pd(OAc) ₂	TBHP	0
12	Pd(OAc) ₂	Na2CO3 · 1.5H2O2	0
13	Pd(OAc) ₂	AgOAc	0
14	Pd(OAc) ₂	Cu(OAc) ₂	0
15	Pd(OAc) ₂	PhI(OAc) ₂	38

Table S-2 Effects of catalyst and oxidants

^{*a*} Yields based on substrate and detected by ¹H NMR analysis using CH₂Br₂ as internal standard. Conditions: **1a** (0.1 mmol), catalyst (0.01 mmol), oxidant (0.2 mmol), Ms₂O (0.07 mmol), TFE (0.3 mL), 80 °C, 24 h.

Entry	$Pd(OAc)_2 \pmod{\%}$	Yield (%)
1	1	16
2	3	39
3	5	66
4	10	70
5	20	70

Table S-3 Effects of the amount of Pd(OAc)₂^{*a*}

^{*a*} Yields based on substrate and detected by ¹H NMR analysis using CH₂Br₂ as internal standard. Conditions: **1a** (0.1 mmol), Pd(OAc)₂, K₂S₂O₈ (0.2 mmol), Ms₂O (0.07 mmol), TFE (0.3 mL), 80 °C, 24 h.

Table S-4 Effects of temperature ^{*a*}

Entry	T (°C)	Yield (%)
1	60	63
2	70	67
3	80	70
4	90	65
5	100	60

^{*a*} Yields based on substrate and detected by ¹H NMR analysis using CH₂Br₂ as internal standard. Conditions: **1a** (1.0 mmol), Pd(OAc)₂ (0.01 mmol), K₂S₂O₈ (0.2 mmol), Ms₂O (0.07 mmol), TFE (0.3 mL), heat, 24 h.

Table S-5 Effects of the amount of K₂S₂O₈ ^{*a*}

Entry	K ₂ S ₂ O ₈ (equiv)	Yield (%)
1	1.0	45

2	1.5	52
3	2.0	70
4	2.5	69
5	3.0	61

^{*a*} Yields based on substrate and detected by ¹H NMR analysis using CH₂Br₂ as internal standard. Conditions: **1a** (1.0 mmol), Pd(OAc)₂ (0.01 mmol), K₂S₂O₈, Ms₂O (0.07 mmol), TFE (0.3 mL), 80 °C, 24 h.

3. Screening the reaction conditions for β -fluoramides

Table S-6 Optimization for 3-fluoro-2,2-dimethyl-N-(4-nitrobenzyl)propanamide (3a) ^a

O ₂ N		[∼] OMs <u>K</u> F	F, solvent, heat	O_2N H F O_2N F	N
- 2	2a			3a	4a
	Entry	Solvent	T (°C)	Yield	_
	1	MeOH	80	7% 3a +16% 4a	_
	2	EtOH	80	9% 3a +37% 4a	
	3	CH ₃ CN	80	trace	
	4	THF	80	0	
	5	Acetone	80	10% 4a	
	6	CHCl ₃	80	0	
	7	DMF	80	34% 4a	
	8	DMSO	80	30% 4a	
	9	TFE	80	14% 3a +5% 4a	
	10	EA	80	0	
	11	TFE	80	24% 3a +10% 4a	
	12	TFE ^b	80	20% 3a +10% 4a	
	13	HFIP	80	19% 4a	
	14	i-PrOH	80	0	

18% 3a +8% 4a	90	TFE	15
58% 3a	100	TFE	16
78% 3a +5% Etherification product	110	TFE	17
83% 3a +5% Etherification product	110	TFE ^c	18

^{*a*} Yields based on substrate and detected by ¹H NMR analysis using CH_2Br_2 as internal standard. Conditions: **2a** (0.1 mmol), KF (0.5 mmol), solvent (1 mL), 20 h. ^{*b*} KF (1 mmol). ^{*c*} 26 h.

4. Screening the reaction conditions for β -lactams

O_2N P	OMs	vent, 80 °C ► O ₂ N	
Entry	Base	Solvent	Yield (%)
1	TEA	EA	0
2	TEA	EtOH	12
3	TEA	CHCl ₃	0
4	TEA	DMF	0
5	TEA	DCM	12
6	TEA	Acetone	0
7	TEA	DMSO	0
8	TEA	Toluene	0
9	K ₂ CO ₃	MeOH	0
10	K ₂ CO ₃	EtOH	0
11	K ₂ CO ₃	DCM	25
12	K ₂ CO ₃	CH ₃ CN	99


Table S-7 Optimization for 3,3-dimethyl-1-(4-nitrobenzyl)azetidin-2-one (4a) ^a

^{*a*} Yields based on substrate and detected by ¹H NMR analysis using CH_2Br_2 as internal standard. Conditions: **2a** (0.1 mmol), TEA (0.5 mmol) or K_2CO_3 (0.2 mmol), solvent (1 mL), 80 °C, 22 h.

III. Preparations and Characterization of Compounds and NMR Spectra

1. Preparations and characterization of compounds

(1) The amide substrates



N-(4-Nitrobenzyl)pivalamide (1a)

Light yellow solid.

Mp (melting point): 122-124 °C (ref 1: 119-121 °C).


¹H NMR (400 MHz, CDCl₃) δ 8.18 (d, *J* = 8.8 Hz, 2H), 7.41 (d, *J* = 8.8 Hz, 2H), 6.13 (br s, 1H), 4.53 (d, *J* = 6.0 Hz, 2H), 1.25 (s, 9H).

¹³C NMR (100 MHz, CDCl₃) δ 178.7 (C=O), 147.2 (C), 146.5 (C), 128.0 (CH), 123.9


(CH), 42.8 (CH₂), 38.8 (C), 27.6 (CH₃).

DEPT-135 (100 MHz, CDCl₃) & 128.0 (upward), 123.9 (upward), 42.8 (downward),

27.6 (upward).



Preparation of N-(2-nitrobenzyl)pivalamide (1b) (ref 2)



2-(2-Nitrobenzyl)isoindoline-1,3-dione (1b-1)

To a solution of 1-(chloromethyl)-2-nitrobenzene (**1b-0**) (5.0 g, 29.2 mmol) in DMF (40 mL) was added phthalimide (5.2 g, 35.4 mmol), and K₂CO₃ (8.4 g, 60.9 mmol). The mixture was stirred at room temperature overngiht. Water (200 mL) was added, and the precipitate was collected by filtration. The cake was washed with water (20 mL*2) and dried in vacuo to give a dark brown solid (**1b-1**) (7.7 g, 94%). Mp: 215-217 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.05 (dd, *J* = 1.2, 8.0 Hz, 1H), 7.92-7.90 (m, 2H), 7.79-7.76 (m, 2H), 7.54 (dt, *J* = 1.2, 8.0 Hz, 1H), 7.54 (dt, *J* = 1.2, 8.0 Hz, 1H), 7.25 (d, *J* = 8.0 Hz, 1H), 5.30 (s, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 167.9 (C=O), 148.1 (C), 134.4 (CH), 133.8 (CH), 131.9 (C), 131.7 (C), 128.5 (CH), 128.1


(CH), 125.4 (CH), 123.7 (CH), 38.7 (CH₂); DEPT-135 (100 MHz, CDCl₃) δ 134.4 (upward), 133.8 (upward), 128.5 (upward), 128.1 (upward), 125.4 (upward), 123.7 (upward), 38.7 (downward).

(2-Nitrophenyl)methanamine (1b-2)


To a solution of **1b-1** (2.3 g, 8.2 mmol) in THF (20 mL) were added hydrazine monohydrate (2 g, 34 mmol) and p-toluenesulfonic acid monohydrate (PTSA) (150 mg, 0.8 mmol). The mixture was heated under reflux for 6 h. The resulting mixture was cooled to room temperature, basified with aqueous 5% potassium carbonate solution to pH=10, and extracted with dichloromethane three times. The organic layers were combined, washed with water, dried over magnesium sulfate, and concentrated in vacuo to give **1b-2** (1.2 g, 93%), which was used directly in the following step without further purification.

N-(2-Nitrobenzyl)pivalamide (1b)

To a stirring solution of **1b-2** (1.2 g, 7.9 mmol), Et₃N (1.2 g, 11.9 mmol) in DCM (20 mL), was added trimethylacetylchloride (PivCl) (1.1 g, 9.1 mmol) at 0 °C (ice/water bath). The reaction mixture was stirred at rt overnight. After that, the reaction mixture was quenched with water (20 mL), and extracted with DCM (10 mL*3), washed with aq.K₂CO₃, brine, and dried over MgSO₄. Then, the combined extracts were concentrated and recrystallization from hexane-EtOAc mixture to afford *N*-(2-nitrobenzyl)pivalamide (**1b**) (gray solid), (1.7 g, yield: 92%). Mp: 112-114 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.05 (d, *J* = 8.8 Hz, 1H), 7.67-7.60 (m, 2H), 7.49-7.45 (m, 1H), 6.56 (br s, 1H), 4.67 (d, *J* = 6.4 Hz, 2H), 1.20 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 178.6 (C=O), 148.5 (C), 134.0 (CH), 133.9 (C), 132.5 (CH), 128.6 (CH), 125.0 (CH), 41.4 (CH₂), 38.8 (C), 27.5 (CH₃); DEPT-135 (100 MHz, CDCl₃) δ 134.1 (upward), 132.5 (upward), 128.6 (upward), 125.1 (upward), 41.4 (downward), 27.5 (upward).



Preparation of N-(3-nitrobenzyl)pivalamide (1c)



2-(3-Nitrobenzyl)isoindoline-1,3-dione (1c-1)

The similar method to **1b-1**, using **1c-0** (5 g, 33 mmol) as starting material to obtain **1c-1** as a light brown solid (8.6 g, 93%). Mp: 164-165 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.29 (t, J = 1.2Hz, 1H), 8.16 (dt, J = 1.2, 8.0 Hz, 1H), 7.91-7.87 (m, 2H), 7.79-7.75 (m, 3H), 7.53 (t, J = 8.0 Hz, 1H), 4.96 (s, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 167.8 (C=O), 148.4 (C), 134.7 (CH), 134.3 (CH), 131.9 (C), 129.8 (CH), 123.6 (CH), 123.5 (CH), 123.0 (CH), 40.8 (CH₂); DEPT-135 (100 MHz, CDCl₃) δ 134.7 (upward), 134.3


(upward), 129.8 (upward), 123.6 (upward), 123.5 (upward), 123.0 (upward), 40.8 (downward).

(3-Nitrophenyl)methanamine (1c-2)

The similar method to **1b-2**, giving **1c-2** as a brown solid (90%), which was used directly in the following step without further purification.

N-(3-Nitrobenzyl)pivalamide (1c)

The similar method to **1b**, giving **1c** as a light yellow solid (87%). Mp: 75-78 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.12-8.10 (m, 2H), 7.62 (d, *J* = 7.6 Hz, 1H), 7.51 (t, *J* = 7.6 Hz, 1H), 6.29 (br s, 1H), 4.54 (d, *J* = 6.0 Hz, 2H), 1.26 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 178.8 (C=O), 148.4 (C), 141.1 (C), 133.6 (CH), 129.6 (CH), 122.3 (CH), 122.0 (CH), 42.7 (CH₂), 38.8 (C), 27.6 (CH₃); DEPT-135 (100 MHz, CDCl₃) δ 133.6 (upward), 129.6 (upward), 122.3 (upward), 122.0 (upward), 42.7 (downward), 27.6 (upward).



N-(4-(Trifluoromethyl)benzyl)pivalamide (1d)

White solid.


Mp: 111-114 °C (ref 3: 114-119 °C).

¹H NMR (400 MHz, CDCl₃) δ 7.59 (d, *J* = 8.0 Hz, 2H), 7.37 (d, *J* = 8.0 Hz, 2H), 6.16 (br s, 1H), 4.50 (d, *J* = 6.0 Hz, 2H), 1.25 (s, 9H).

¹³C NMR (100 MHz, CDCl₃) δ 178.6 (C=O), 142.9 (C), 129.6 (C), 127.7 (CH), 125.6 (CH), 124.1 (CF₃), 43.0 (CH₂), 38.8 (C), 27.6 (CH₃).

DEPT-135 (100 MHz, CDCl₃) δ 127.7 (upward), 125.6 (upward), 43.0 (downward), 27.6 (upward).

¹⁹F NMR (376 MHz, CDCl₃) δ -62.5.



N-(2-(Trifluoromethyl)benzyl)pivalamide (1e)

White solid.

Mp: 81-85 °C (ref 3: 82-85 °C).


¹H NMR (400 MHz, CDCl₃) δ 7.65 (d, J = 8.0 Hz, 2H), 7.52-7.50 (m, 2H), 7.40-7.36 (m, 1H), 6.14 (br s, 1H), 4.61 (d, J = 6.0 Hz, 2H), 1.21 (s, 9H).

¹³C NMR (100 MHz, CDCl₃) δ 178.4 (C=O), 137.0 (C), 132.3 (CH), 130.4 (CH),

128.1 (C), 127.5 (CH), 126.0 (CH), 124.5 (CF₃), 40.2 (CH₂), 38.7 (C), 27.5 (CH₃).

DEPT-135 (100 MHz, CDCl₃) δ 132.3 (upward), 130.4 (upward), 127.5 (upward), 126.0 (upward), 40.2 (downward), 27.5 (upward).

¹⁹F NMR (376 MHz, CDCl₃) δ -59.6.



N-(3-(Trifluoromethyl)benzyl)pivalamide (1f)

Light yellow solid.


Mp: 72-75 °C (ref 3: 73-76 °C).

¹H NMR (400 MHz, CDCl₃) δ 7.54-7.28 (m, 4H), 6.16 (br s, 1H), 4.50 (d, *J* = 6.0 Hz, 2H), 1.25 (s, 9H).


¹³C NMR (100 MHz, CDCl₃) δ 178.6 (C=O), 139.9 (C), 131.0 (C), 130.9 (CH), 129.2 (CH), 124.1 (CH), 124.0 (CF₃), 43.0 (CH₂), 38.8 (C), 27.6 (CH₃).

DEPT-135 (100 MHz, CDCl₃) δ 130.8 (upward), 129.2 (upward), 124.1 (upward), 42.9 (downward), 27.6 (upward).

¹⁹F NMR (376 MHz, CDCl₃) δ -62.7.



Preparation of methyl 4-(pivalamidomethyl)benzoate (1g) (ref 4)




Methyl 4-(aminomethyl)benzoate (1g-1)

A solution of 4-(aminomethyl)benzoic acid (**1g-0**) (5.0 g, 33.1 mmol) in MeOH (30 mL) were cooled to 0 °C. To this solution, SOCl₂ (3.5 mL, 43.7 mmol) was added dropwise in 30 min. The cooling bath was removed, and the mixture was stirred at rt overnight. The volatile solvent was evaporated to give **1g-1** as hydrochloride salt (99%). Mp: 264-267 °C. ¹H NMR (400 MHz, DMSO-d₆) δ 8.80 (br s, 2H), 7.97 (d, *J* = 8.0 Hz, 2H), 7.68 (d, *J* = 8.0 Hz, 2H), 4.10 (s, 2H), 3.86 (s, 3H); ¹³C NMR (100 MHz, DMSO-d₆) δ 166.4 (C=O), 139.9 (C), 129.9 (CH), 129.7 (C), 52.7 (CH₃), 42.1 (CH₂); DEPT-135 (100 MHz, DMSO-d₆) δ 129.7 (upward), 52.7 (upward), 42.1 (downward).

Methyl 4-(pivalamidomethyl)benzoate (1g)

To a stirring solution of **1g-1** (1.65 g, 10 mmol), Et₃N (1.8 g, 18 mmol) in DCM (20 mL), was added trimethylacetylchloride (PivCl) (1.3 g, 11 mmol) at 0 °C (ice/water bath). The reaction mixture was stirred at rt overnight. After that, the reaction mixture was quenched with water (20 mL), and extracted with DCM (10 mL*3), washed with aq.K₂CO₃, brine, and dried over MgSO₄. Then, the combined extracts were concentrated and recrystallization from hexane-EtOAc mixture to afford methyl 4-(pivalamidomethyl)benzoate (**1g**) (white solid) (2.17 g, yield: 87%). Mp: 94-96 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.99 (d, *J* = 8.0 Hz, 2H), 7.32 (d, *J* = 8.0 Hz, 2H), 6.14 (br s, 1H), 4.49 (d, *J* = 6.4 Hz, 2H), 3.91 (s, 3H), 1.25 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 178.5 (C=O), 166.9 (CO₂), 144.1 (C), 130.0 (CH), 129.2 (C), 127.3 (CH), 52.1 (CH₃), 43.1 (CH₂), 38.8 (C), 27.6 (CH₃); DEPT-135 (100 MHz, CDCl₃) δ 130.0 (upward), 127.3 (upward), 52.1 (upward), 43.1 (downward), 27.6 (upward).



N-(4-(Methylsulfonyl)benzyl)pivalamide (1h)

White solid.

Mp: 161-163 °C.

¹H NMR (400 MHz, CDCl₃) δ 7.80 (d, *J* = 8.0 Hz, 2H), 7.39 (d, *J* = 8.0 Hz, 2H), 6.44 (br s, 1H), 4.50 (d, *J* = 6.0 Hz, 2H), 3.02 (s, 3H), 1.25 (s, 9H).

¹³C NMR (100 MHz, CDCl₃) δ 178.8 (C=O), 145.6 (C), 139.0 (C), 128.0 (CH), 127.6 (CH), 44.6 (CH₃), 42.8 (CH₂), 38.8 (C), 27.6 (CH₃).

DEPT-135 (100 MHz, CDCl₃) δ 128.0 (upward), 127.6 (upward), 44.6 (upward), 42.8 (downward), 27.6 (upward).

C N H H

N-(4-Fluorobenzyl)pivalamide (1i)

Light yellow solid.


Mp: 79-82 °C (ref 3: 80-82 °C).

¹H NMR (400 MHz, CDCl₃) δ 7.25-7.22 (m, 2H), 7.02 (t, *J* = 8.8 Hz, 2H), 6.02 (br s, 1H), 4.40 (d, *J* = 6.4 Hz, 2H), 1.23 (s, 9H).

¹³C NMR (100 MHz, CDCl₃) δ 178.4 (C=O), 162.1 (CF), 134.5 (C), 129.2 (CH), 115.5 (CH), 42.8 (CH₂), 38.7 (C), 27.6 (CH₃).

DEPT-135 (100 MHz, CDCl₃) δ 129.2 (upward), 115.5 (upward), 42.8 (downward), 27.6 (upward).

¹⁹F NMR (376 MHz, CDCl₃) δ -115.2.



N-(4-Chlorobenzyl)pivalamide (1j)


White solid.

Mp: 101-104 °C (ref 3: 101-105 °C).

¹H NMR (400 MHz, CDCl₃) δ 7.32 (d, *J* = 8.4 Hz, 2H), 7.21 (d, *J* = 8.4 Hz, 2H), 5.95 (br s, 1H), 4.42 (d, *J* = 6.0 Hz, 2H), 1.25 (s, 9H).

¹³C NMR (100 MHz, CDCl₃) δ 178.4 (C=O), 137.3 (C), 133.2 (C), 129.0 (CH), 128.8 (CH), 42.9 (CH₂), 38.7 (C), 27.6 (CH₃).

DEPT-135 (100 MHz, CDCl₃) δ 129.0 (upward), 128.8 (upward), 42.9 (downward), 27.6 (upward).



N-(4-Bromobenzyl)pivalamide (1k)


White crystal.

Mp: 106-109 °C (ref 3: 105-108 °C).

¹H NMR (400 MHz, CDCl₃) δ 7.46 (d, *J* = 8.4 Hz, 2H), 7.14 (d, *J* = 8.4 Hz, 2H), 6.04 (br s, 1H), 4.39 (d, *J* = 6.0 Hz, 2H), 1.23 (s, 9H).

¹³C NMR (100 MHz, CDCl₃) δ 178.4 (C=O), 137.8 (C), 131.8 (CH), 129.3 (CH), 121.2 (CH), 42.9 (CH₂), 38.7 (C), 27.6 (CH₃).

DEPT-135 (100 MHz, CDCl₃) δ 131.8 (upward), 129.3 (upward), 42.9 (downward), 27.6 (upward).



N-(3,4-Dichlorobenzyl)pivalamide (11)

White solid.

Mp: 121-123 °C (ref 3: 120-123 °C).

¹H NMR (400 MHz, CDCl₃) δ 7.37 (d, *J* = 8.0 Hz, 1H), 7.31 (d, *J* = 2.0 Hz, 1H), 7.08 (dd, *J* = 2.0, 8.0 Hz, 1H), 6.24 (br s, 1H), 4.36 (d, *J* = 6.0 Hz, 2H), 1.23 (s, 9H).

¹³C NMR (100 MHz, CDCl₃) δ 178.6 (C=O), 139.2 (C), 132.6 (C), 131.2 (C), 130.6

(CH), 129.3 (CH), 126.8 (CH), 42.3 (CH₂), 38.7 (C), 27.6 (CH₃).

DEPT-135 (100 MHz, CDCl₃) δ 130.6 (upward), 129.3 (upward), 126.8 (upward), 42.3 (downward), 27.6 (upward).

∼_N,

N-butylpivalamide (1m)

Light yellow liquid.

¹H NMR (400 MHz, CDCl₃) δ 5.63 (br s, 1H), 3.25 (dd, J = 6.8, 12.8 Hz, 2H), 1.53-1.46 (m, 2H), 1.40-1.31 (m, 2H), 1.21 (s, 9H), 0.94 (t, J = 7.2 Hz, 3H).

¹³C NMR (100 MHz, CDCl₃) δ 178.3 (C=O), 39.3 (CH₂), 38.6 (C), 31.7 (CH₂), 27.6 (CH₃), 20.1 (CH₂), 13.8 (CH₃).

DEPT-135 (100 MHz, CDCl₃) δ 39.3 (downward), 31.7 (downward), 27.6 (upward), 20.1 (downward), 13.8 (upward).

L O N

N-(Pentan-3-yl)pivalamide (1n)

White crystal.

Mp: 114-117 °C (ref 3: 118-122 °C).

¹H NMR (400 MHz, CDCl₃) δ 5.29 (br s, 1H), 3.82-3.76 (m, 1H), 1.62-1.51 (m, 2H), 1.42-1.31 (m, 2H), 1.22 (s, 9H), 0.89 (t, J = 7.6 Hz, 6H).

¹³C NMR (100 MHz, CDCl₃) δ 178.1 (C=O), 51.5 (CH), 38.7 (C), 27.7 (CH₃), 27.6 (CH₃), 10.2 (CH₃).

DEPT-135 (100 MHz, CDCl₃) δ 51.5 (upward), 27.7 (upward), 27.6 (downward), 10.2 (upward).

N-(tert-Butyl)pivalamide (10)


White crystal.

Mp: 115-117 °C (ref 5:117-118 °C).

¹H NMR (400 MHz, CDCl₃) δ 5.41 (br s, 1H), 1.34 (s, 9H), 1.16 (s, 9H).

¹³C NMR (100 MHz, CDCl₃) δ 177.8 (C=O), 50.7 (C), 39.0 (C), 28.7 (CH₃), 27.7 (CH₃).

DEPT-135 (100 MHz, CDCl₃) δ 28.7 (upward), 27.7 (upward).



N-Cyclohexylpivalamide (1p)

White solid.

Mp: 124-127 °C (ref 3:122-124 °C).

¹H NMR (400 MHz, CDCl₃) δ 5.48 (br s, 1H), 3.77-3.69 (m, 1H), 1.90-1.86 (m, 2H), 1.71-1.66 (m, 2H), 1.63-1.57 (m, 1H), 1.41-1.30 (m, 2H), 1.17 (s, 9H), 1.15-1.05 (m, 2H).

¹³C NMR (100 MHz, CDCl₃) δ 177.4 (C=O), 47.9 (CH), 38.5 (C), 33.1 (CH₂), 27.6 (CH₃), 25.6 (CH₂), 24.9 (CH₂).

DEPT-135 (100 MHz, CDCl₃) δ 47.9 (upward), 33.1 (downward), 27.6 (upward), 25.6 (downward), 24.9 (downward).

N-Cyclopentylpivalamide (1q)

White crystal.

Mp: 125-128 °C (ref 3:126-130 °C).

¹H NMR (400 MHz, CDCl₃) δ 5.55 (br s, 1H), 4.20-4.12 (m, 1H), 2.04-1.94 (m, 2H), 1.70-1.56 (m, 4H), 1.37-1.28 (m, 2H), 1.17 (s, 9H).

¹³C NMR (100 MHz, CDCl₃) δ 177.9 (C=O), 51.0 (CH), 38.4 (C), 33.2 (CH₂), 27.6 (CH₃), 23.8 (CH₂).

DEPT-135 (100 MHz, CDCl₃) δ 51.0 (upward), 33.1 (downward), 27.6 (upward), 23.8 (downward).

N

N-Cyclobutylpivalamide (1r)


White crystal.

Mp: 133-135 °C (ref 3:120-125 °C).

¹H NMR (400 MHz, CDCl₃) δ 5.77 (br s, 1H), 4.41-4.31 (m, 1H), 2.37-2.30 (m, 2H), 1.87-1.77 (m, 2H), 1.73-1.65 (m, 2H), 1.17 (s, 9H).

¹³C NMR (100 MHz, CDCl₃) δ 177.5 (C=O), 44.7 (CH), 38.4 (C), 31.3 (CH₂), 27.6 (CH₃), 15.0 (CH₂).

DEPT-135 (100 MHz, CDCl₃) δ 44.7 (upward), 31.2 (downward), 27.5 (upward), 15.0 (downward).




N-(2-Methoxyethyl)pivalamide (1s)

Light yellow liquid.


¹H NMR (400 MHz, CDCl₃) δ 6.09 (br s, 1H), 3.35-3.28 (m, 4H), 3.24 (s, 3H), 1.08 (s, 9H).

¹³C NMR (100 MHz, CDCl₃) δ 178.4 (C=O), 71.1 (CH₂), 58.6 (CH₃), 39.1 (CH₂), 38.5 (C), 27.4 (CH₃).

DEPT-135 (100 MHz, CDCl₃) δ 71.1 (downward), 58.6 (upward), 39.1 (downward), 27.4 (upward).



Preparation of 2,2-dimethyl-N-(4-nitrobenzyl)butanamide (1t) (ref 6)




2,2-Dimethylbutanoyl chloride (1t-1)

Under nitrogen atmosphere, oxalyl chloride (640 mg, 5 mmol) was added dropwise to a solution of 2,2-dimethylbutyric acid (**1t-0**) (488 mg, 4.2 mmol) in dichloromethane (10 mL) over a period of 1 minute. The reaction mixture was stirred at rt for 60 minutes. Dichloromethane and oxalyl chloride were distilled under reduced pressure. The crude product (**1t-1**) (566 mg, yield: 100%) was used immediately in the following step without further purification.


2,2-Dimethyl-N-(4-nitrobenzyl)butanamide (1t)

To a stirring solution of (4-nitrophenyl)methanamine hydrochloride (**1t-2**) (500 mg, 3.5 mmol), Et₃N (884 mg, 8.75 mmol) in DCM (20 mL), was added 2,2-dimethylbutanoyl chloride (**1t-1**) (566 mg, 4.2 mmol) at 0 °C (ice/water bath). The reaction mixture was allowed to warm to room temperature, and stirred at rt overnight. After that, the reaction mixture was quenched with water (30 mL), and extracted with DCM (5 mL*3), washed with aq.K₂CO₃, brine, and dried over MgSO₄. Then, the combined extracts were concentrated and recrystallization from hexane-EtOAc mixture to afford 2,2-dimethyl-*N*-(4-nitrobenzyl)butanamide (**1t**) (yellow solid) (720 mg, yield: 82%). Mp: 80-82 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.15 (d, *J* = 8.4 Hz, 2H), 7.41 (d, *J* = 8.4 Hz, 2H), 6.31 (br s, 1H), 4.53 (d, *J* = 6.4 Hz, 2H), 1.59 (q, *J* = 7.2 Hz, 2H), 1.20 (s, 6H), 0.85 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 178.1 (C=O), 147.1 (C), 146.6 (C), 128.1 (CH), 123.8 (CH), 42.8 (CH₂), 42.5 (C), 33.8 (CH₂), 24.9 (CH₃), 9.2 (CH₃); DEPT-135 (100 MHz, CDCl₃) δ 128.1 (upward),

123.8 (upward), 42.8 (downward), 33.8 (downward), 25.0 (upward), 9.2 (upward).



Preparation of 2,2-dimethyl-N-(4-nitrobenzyl)hexanamide (1u) (ref 7)



Methyl 2,2-dimethylhexanoate (1u-1)

A solution of lithium diisopropylamide (LDA) (2M in THF) (5 mL, 1.5 mmol) in THF (15 mL) was cooled to -78 °C. Then methylisobutyrate (**1u-0**) (1.02g, 10 mmol) was added dropwise at this temperature in 10 min. The resulting mixture was stirred at -78 °C for 30 min. Then a solution of n-BuI (2.76g, 15 mmol) in THF (5 mL) was added carefully. The reaction was continued for 2 h, and slowly warmed to rt. The reaction mixture was quenched with saturated NH₄Cl, extracted with EtOAc (3×15 mL). The organic layer was dried over MgSO₄, and the solvent was filtered, evaporated under reduced pressure to give the crude product (**1u-1**) (1.1 g, 70%). ¹H NMR (400 MHz, CDCl₃) δ 3.65 (s, 3H), 1.52-1.48 (m, 2H), 1.30-1.25 (m, 4H), 1.21-1.13 (m, 2H), 1.15 (s, 6H), 0.88 (t, *J* = 7.2 Hz, 3H).

2,2-Dimethylhexanoic acid (1u-2)

To a solution of **1u-1** (1.1g, 7 mmol) in THF/MeOH/H₂O (1:1:1) (6 mL) was added LiOH·H₂O (1.26 g, 30 mmol). The mixture was stirred at rt overnight. The volatile was evaporated under reduced pressure. Then the reaction mixture was acidified with conc. HCl and extracted with CH₂Cl₂. The organic layer was dried over MgSO₄, filtered and concentrated under vaccum to give the desired carboxylic acid (**1u-2**) as a slurry (960 mg, 95%).


2,2-Dimethylhexanoyl chloride (1u-3)

Under nitrogen atmosphere, oxalyl chloride (1.1 g, 8.7 mmol) was added dropwise to a solution of 2,2-dimethylhexanoic acid (**1u-2**) (960 mg, 6.7 mmol) in dichloromethane (10 mL) over a period of 5 minutes. The reaction mixture was stirred at rt for 1.5 h. Dichloromethane and oxalyl chloride were distilled under reduced pressure. The crude product (**1u-3**) (1.09 g, yield: 100%) was used immediately in the following step without further purification.


2,2-Dimethyl-N-(4-nitrobenzyl)hexanamide (1u)

To a stirring solution of (4-nitrophenyl)methanamine hydrochloride (1u-4) (890 mg,

4.7 mmol), Et₃N (1.52 g, 15 mmol) in DCM (20 mL), was added 2,2-dimethylhexanoyl chloride (**1u-3**) (1.09 g, 6.7 mmol) at 0 °C (ice/water bath). The reaction mixture was allowed to warm to room temperature, and stirred at rt overnight. After that, the reaction mixture was quenched with water (50 mL), and extracted with DCM (10 mL*3), washed with aq.K₂CO₃, brine, and dried over MgSO₄. The combined extracts were concentrated. The crude mixture was purified through silica gel column chromatography eluting with n-hexane/EtOAc (5:1) to afford 2,2-dimethyl-*N*-(4-nitrobenzyl)hexanamide (**1u**) (orange solid) (980 mg, yield: 75%). Mp: 57-60 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.21 (d, *J* = 8.8 Hz, 2H), 7.45 (d, *J* = 8.8 Hz, 2H), 6.10 (br s, 1H), 4.57 (d, *J* = 6.0 Hz, 2H), 1.58-1.53 (m, 2H), 1.32-1.21 (m, 4H), 1.23 (s, 6H), 0.90 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 178.2 (C=O), 147.2 (C), 146.5 (C), 128.1 (CH), 123.9 (CH), 42.8 (CH₂), 42.2 (C), 41.1 (CH₂), 27.1 (CH₂), 25.4 (CH₃), 23.2 (CH₂), 14.0 (CH₃); DEPT-135 (100 MHz, CDCl₃) δ 128.1 (upward), 123.8 (upward), 42.8 (downward), 41.1 (downward), 27.1 (downward), 25.4 (upward), 23.2 (downward), 14.0 (upward).



Preparation of N-(4-nitrobenzyl)isobutyramide (1v)




Isobutyryl chloride (1v-1)

Under nitrogen atmosphere, oxalyl chloride (640 mg, 5 mmol) was added dropwise to a solution of isobutyric acid (**1v-0**) (370 mg, 4.2 mmol) in dichloromethane (10 mL) over a period of 1 minute. The reaction mixture was stirred at rt for 60 minutes . Dichloromethane and oxalyl chloride were distilled under reduced pressure. The crude product (**1v-1**) (447 mg, yield: 100%) was used immediately in the following step without further purification.

N-(4-Nitrobenzyl)isobutyramide (1v)

To a stirring solution of (4-nitrophenyl)methanamine hydrochloride (**1v-2**) (500 mg, 3.5 mmol), Et₃N (884 mg, 8.75 mmol) in DCM (20 mL), was added isobutyryl chloride (**1v-1**) (447 mg, 4.2 mmol) at 0 °C (ice/water bath). The reaction mixture was allowed to warm to room temperature, and stirred at rt overnight. After that, the reaction mixture was quenched with water (30 mL), and extracted with DCM (5 mL*3), washed with aq.K₂CO₃, brine, and dried over MgSO₄. Then, the combined extracts were concentrated and recrystallization from n-hexane/EtOAc mixture to afford *N*-(4-nitrobenzyl)isobutyramide (**1v**) (yellow solid) (624 mg, yield: 67%). Mp: 95-99 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.21 (d, *J* = 8.8 Hz, 2H), 7.45 (d, *J* = 8.8 Hz, 2H), 5.94 (br s, 1H), 4.57 (d, *J* = 6.0 Hz, 2H), 2.50-2.43 (m, 1H), 1.23 (d, *J* = 7.2 Hz, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 177.4 (C=O), 147.1 (C), 146.5 (C), 128.2 (CH),

123.8 (CH), 42.7 (CH₂), 35.5 (CH), 19.7 (CH₃); DEPT-135 (100 MHz, CDCl₃) δ 128.2 (upward), 123.8 (upward), 42.7 (downward), 35.5 (upward), 19.7 (upward).



N-(4-nitrobenzyl)propionamide (1w)


Light yellow solid.

Mp: 105-109 °C.


¹H NMR (400 MHz, CDCl₃) δ 8.13 (d, *J* = 8.8 Hz, 2H), 7.41 (d, *J* = 8.8 Hz, 2H), 6.41 (br s, 1H), 4.51 (d, *J* = 6.4 Hz, 2H), 2.30 (q, *J* = 7.6 Hz, 2H), 1.18 (t, *J* = 7.6 Hz, 3H).

¹³C NMR (100 MHz, CDCl₃) δ 174.2 (C=O), 147.1 (C), 146.3 (C), 128.2 (CH), 123.8 (CH), 42.7 (CH₂), 29.5 (CH₂), 9.8 (CH₃).

DEPT-135 (100 MHz, CDCl₃) δ 128.1 (upward), 123.8 (upward), 42.7 (downward), 29.5 (downward), 9.8 (upward).



Preparation of N-neopentylpivalamide (1x) (ref 8)



2,2-Dimethylpropan-1-amine (1x-1)

To a slurry of lithium aluminum hydride (LiAlH₄) (550 mg, 14.5 mmol) in anhydrous ether (10 mL) was added trimethylacetonitrile (**1x-0**) (1.0 g, 12 mmol) at 0 °C (ice/water bath) under nitrogen atmosphere. The cooling bath was removed and the mixture was stirred at rt overnight. The mixture was cooled to 0 °C again, and hydrolyzed with water (550 mg). After the addition of 15% sodium hydroxide solution (0.55 mL), water (1.75 g) was added again. The ether layer was separated, dried over MgSO₄. After filtration, the solution of **1x-1** was used directly in the following step.

N-Neopentylpivalamide (1x)

To the above solution of **1x-1** (1.04 g, 12 mmol), Et_3N (1.82 g, 18 mmol) and trimethylacetylchloride (PivCl) (1.75 g, 14.5 mmol) were added in sequence at 0 °C (ice/water bath). The reaction mixture was allowed to warm to room temperature, and stirred at rt overnight. After that, the reaction mixture was quenched with water (50 mL), and extracted with Et_2O (10 mL*3), washed with aq.K₂CO₃, brine, and dried over MgSO₄. The combined extracts were concentrated. The crude mixture was

purified through silica gel column chromatography eluting with n-hexane/EtOAc (1:1) to afford *N*-neopentylpivalamide (**1x**) (white solid) (1.4 g, yield: 70%). Mp: 89-90 °C. ¹H NMR (400 MHz, CDCl₃) δ 5.70 (br s, 1H), 3.08 (d, *J* = 6.4 Hz, 2H), 1.23 (s, 9H), 0.92 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 178.3 (C=O), 50.3 (CH₂), 38.9 (C), 32.0 (C), 27.7 (CH₃), 22.2 (CH₃); DEPT-135 (100 MHz, CDCl₃) δ 50.3 (downward), 27.7 (upward), 27.2 (upward).

References:

(1) Steffel, L. R.; Cashman, T. J.; Reutershan, M. H.; Linton, B. R. J. Am. Chem. Soc. **2007**, *129*, 12956.

(2) Katayama, S.; Ae, N.; Kodo, T.; Masumoto, S.; Hourai, S.; Tamamura, C.; Tanaka, H.; Nagata, R. *J. Med. Chem.* **2003**, *46*, 691.

(3) Zhou, L.; Lu, W. Org. Lett. 2014, 16, 508.

(4) Suchý, M.; Milne, M.; Elmehriki, A. A. H.; McVicar, N.; Li, A. X.; Bartha, R.;

Hudson, R. H. E. J. Med. Chem. 2015, 58, 6516.

(5) Shi, F.; Li, J.; Li, C.; Jia, X. Tetrahedron Lett. 2010, 51, 6049.


(6) Giri, R.; Chen, X.; Yu, J.-Q. Angew. Chem. Int. Ed. 2005, 44, 2112.

(7) Rit, R. K.; Yadav, R.; Sahoo, A. K. Org. Lett. 2012, 14, 3724.

(8) a) Curtin, D.; Gerber, S. J. Am. Chem. Soc. 1952, 74, 4052. b) Meister, W.; Guthrie, R.

D.; Maxwell, J. L.; Jaeger, D. A.; Cram, D. J. J. Am. Chem. Soc. 1969, 91, 4452.

(2) β -Mesylated amides



2,2-Dimethyl-3-((4-nitrobenzyl)amino)-3-oxopropyl methanesulfonate (2a)

Gray solid (247 mg, 75%). $R_f = 0.50$, 66% EtOAc in n-hexane.


Mp: 81-83 °C.

¹H NMR (400 MHz, CDCl₃) δ 8.23 (d, *J* = 8.8 Hz, 2H), 7.45 (d, *J* = 8.8 Hz, 2H), 6.27 (br s, 1H), 4.59 (d, *J* = 6.0 Hz, 2H), 4.26 (s, 2H), 3.00 (s, 3H), 1.35 (s, 6H).

¹³C NMR (100 MHz, CDCl₃) δ 174.7 (C=O), 147.3 (C), 145.6 (C), 128.0 (CH), 124.0 (CH), 76.0 (CH₂), 43.0 (CH₂), 42.9 (C), 37.0 (CH₃), 22.2 (CH₃).

DEPT-135 (100 MHz, CDCl₃) δ 128.0 (upward), 124.0 (upward), 76.0 (downward), 43.0 (downward), 37.0 (upward), 22.3 (upward).

HRMS (ESI-Q/TOF MS) Calcd for $C_{13}H_{18}N_2O_6S$ [M+Na]⁺: 353.0783; found: 353.0786.



2,2-Dimethyl-3-((2-nitrobenzyl)amino)-3-oxopropyl methanesulfonate (2b)

Brown solid (257 mg, 78%). $R_f = 0.50$, 66% EtOAc in n-hexane.


Mp: 89-91 °C.

¹H NMR (400 MHz, CDCl₃) δ 8.04 (d, *J* = 7.6 Hz, 1H), 7.62-7.59 (m, 2H), 7.48-7.45 (m, 1H), 6.69 (br s, 1H), 4.68 (d, *J* = 6.0 Hz, 2H), 4.16 (s, 2H), 2.90 (s, 3H), 1.25 (s, 6H).

¹³C NMR (100 MHz, CDCl₃) δ 174.6 (C=O), 148.4 (C), 134.1 (CH), 133.3 (C), 132.0 (CH), 128.9 (CH), 125.2 (CH), 75.7 (CH₂), 42.8 (C), 41.6 (CH₂), 36.9 (CH₃), 22.1 (CH₃).

DEPT-135 (100 MHz, CDCl₃) δ 134.1 (upward), 132.0 (upward), 128.9 (upward), 125.3 (upward), 75.8 (downward), 41.6 (downward), 36.9 (upward), 22.1 (upward).

HRMS (ESI-Q/TOF MS) Calcd for $C_{13}H_{18}N_2O_6S$ [M+Na]⁺: 353.0783; found: 353.0788.



2,2-Dimethyl-3-((3-nitrobenzyl)amino)-3-oxopropyl methanesulfonate (2c)

White solid (231 mg, 70%). $R_f = 0.50$, 66% EtOAc in n-hexane.


Mp: 128-130 °C.

¹H NMR (400 MHz, CDCl₃) δ 8.10 (m, 2H), 7.62 (d, *J* = 7.2 Hz, 1H), 7.53-7.49 (m, 1H), 6.56 (br s, 1H), 4.55 (d, *J* = 6.0 Hz, 2H), 4.24 (s, 2H), 2.99 (s, 3H), 1.32 (s, 6H).

¹³C NMR (100 MHz, CDCl₃) δ 174.8 (C=O), 148.4 (C), 140.5 (C), 133.6 (CH), 129.7 (CH), 122.4 (CH), 122.1 (CH), 75.9 (CH₂), 42.9 (CH₂), 42.8 (C), 37.0 (CH₃), 22.2 (CH₃).

DEPT-135 (100 MHz, CDCl₃) δ 133.5 (upward), 129.8 (upward), 122.6 (upward), 122.1 (upward), 75.9 (downward), 42.9 (downward), 37.0 (upward), 22.3 (upward).

HRMS (ESI-Q/TOF MS) Calcd for $C_{13}H_{18}N_2O_6S$ [M+Na]⁺: 353.0783; found: 353.0784.



2,2-Dimethyl-3-oxo-3-((4-(trifluoromethyl)benzyl)amino)propyl

methanesulfonate (2d)

Brown oil (204 mg, 58%). $R_f = 0.55$, 60% EtOAc in n-hexane.


¹H NMR (400 MHz, CDCl₃) δ 7.61 (d, *J* = 8.4 Hz, 2H), 7.39 (d, *J* = 8.4 Hz, 2H), 6.32 (br s, 1H), 4.52 (d, *J* = 6.0 Hz, 2H), 4.23 (s, 2H), 2.95 (s, 3H), 1.32 (s, 6H).

¹³C NMR (100 MHz, CDCl₃) δ 174.6 (C=O), 142.2 (C), 129.8 (C), 127.6 (CH), 125.7 (CH), 124.0 (CF₃), 76.1 (CH₂), 43.2 (CH₂), 42.8 (C), 36.9 (CH₃), 22.2 (CH₃).

DEPT-135 (100 MHz, CDCl₃) δ 127.7 (upward), 125.7 (upward), 76.1 (downward), 43.2 (downward), 36.9 (upward), 22.2 (upward).

¹⁹F NMR (376 MHz, CDCl₃) δ -62.5.

HRMS (ESI-Q/TOF MS) Calcd for $C_{14}H_{18}F_3NO_4S$ [M+Na]⁺: 376.0806; found: 376.0816.



2,2-Dimethyl-3-oxo-3-((2-(trifluoromethyl)benzyl)amino)propyl methanesulfonate (2e)

Gray solid (211 mg, 60%). $R_f = 0.60$, 50% EtOAc in n-hexane.

Mp: 80-82 °C.


¹H NMR (400 MHz, CDCl₃) δ 7.67 (d, *J* = 8.0 Hz,1H), 7.55-7.50 (m, 2H), 7.42-7.38 (m, 1H), 6.27 (br s, 1H), 4.64 (d, *J* = 6.0 Hz, 2H), 4.21 (s, 2H), 2.93 (s, 3H), 1.28 (s, 6H).

¹³C NMR (100 MHz, CDCl₃) δ 174.4 (C=O), 136.3 (C), 132.4 (CH), 130.2 (CH), 128.1 (C), 127.8 (CH), 126.2 (CH), 124.4 (CF₃), 76.0 (CH₂), 42.8 (C), 40.5 (CH₂), 36.8 (CH₃), 22.1 (CH₃).

DEPT-135 (100 MHz, CDCl₃) δ 132.4 (upward), 130.4 (upward), 127.8 (upward), 126.3 (upward), 76.0 (downward), 40.6 (downward), 36.9 (upward), 22.1 (upward).

¹⁹F NMR (376 MHz, CDCl₃) δ -59.6.

HRMS (ESI-Q/TOF MS) Calcd for $C_{14}H_{18}F_3NO_4S$ [M+Na]⁺: 376.0806; found: 376.0799.



2,2-Dimethyl-3-oxo-3-((3-(trifluoromethyl)benzyl)amino)propyl methanesulfonate (2f)

Gray solid (218 mg, 62%). $R_f = 0.55$, 60% EtOAc in n-hexane.

Mp: 67-69 °C.


¹H NMR (400 MHz, CDCl₃) δ 7.53-7.46 (m, 4H), 6.42 (br s, 1H), 4.50 (d, *J* = 5.6 Hz, 2H), 4.22 (s, 2H), 2.94 (s, 3H), 1.30 (s, 6H).

¹³C NMR (100 MHz, CDCl₃) δ 174.6 (C=O), 139.3 (C), 131.0 (C), 130.8 (CH), 129.3 (CH), 124.3 (CH), 124.1 (C), 124.0 (CF₃), 75.9 (CH₂), 43.2 (CH₂), 42.8 (C), 36.9 (CH₃), 22.2 (CH₃).

DEPT-135 (100 MHz, CDCl₃) δ 130.8 (upward), 129.3 (upward), 124.3 (upward), 75.9 (downward), 43.3 (downward), 36.9 (upward), 22.3 (upward).

¹⁹F NMR (376 MHz, CDCl₃) δ -62.7.

HRMS (ESI-Q/TOF MS) Calcd for $C_{14}H_{18}F_3NO_4S$ [M+Na]⁺: 376.0806; found: 376.0815.



Methyl 4-((2,2-dimethyl-3-((methylsulfonyl)oxy)propanamido)methyl)benzoate (2g)


Brown slurry (154 mg, 45%). $R_f = 0.50$, 60% EtOAc in n-hexane.

¹H NMR (400 MHz, CDCl₃) δ 8.01 (d, *J* = 8.0 Hz, 2H), 7.33 (d, *J* = 8.4 Hz, 2H), 6.31 (br s, 1H), 4.52 (d, *J* = 6.0 Hz, 2H), 4.24 (s, 2H), 3.92 (s, 3H), 2.96 (s, 3H), 1.32 (s, 6H).

¹³C NMR (100 MHz, CDCl₃) δ 174.6 (C=O), 166.8 (CO₂), 143.2 (C), 130.1 (CH), 129.4 (C), 127.3 (CH), 76.1 (CH₂), 52.2 (CH₃), 43.3 (CH₂), 42.8 (C), 36.9 (CH₃), 22.2 (CH₃).

DEPT-135 (100 MHz, CDCl₃) δ 130.0 (upward), 127.3 (upward), 76.0 (downward), 52.2 (upward), 43.4 (downward), 36.9 (upward), 22.2 (upward).

HRMS (ESI-Q/TOF MS) Calcd for $C_{15}H_{21}NO_6S$ [M+Na]⁺: 366.0987; found: 366.0991.



2,2-Dimethyl-3-((4-(methylsulfonyl)benzyl)amino)-3-oxopropyl methanesulfonate (2h)

Light brown solid (228 mg, 63%). $R_f = 0.40$, 80% EtOAc in n-hexane.

Mp: 101-103 °C.


¹H NMR (400 MHz, CDCl₃) δ 7.80 (d, J = 8.4 Hz, 2H), 7.39 (d, J = 8.4 Hz, 2H), 6.58 (br s, 1H), 4.53 (d, J = 6.0 Hz, 2H), 4.22 (s, 2H), 3.01 (s, 3H), 2.97 (s, 3H), 1.31 (s,

6H).

¹³C NMR (100 MHz, CDCl₃) δ 175.0 (C=O), 145.0 (C), 139.4 (C), 128.2 (CH), 127.9 (CH), 76.4 (CH₂), 44.8 (CH₃), 43.2 (CH₂), 43.1 (C), 37.2 (CH₃), 22.4 (CH₃).

DEPT-135 (100 MHz, CDCl₃) δ 128.0 (upward), 127.8 (upward), 76.1 (downward), 44.5 (upward), 43.0 (downward), 37.0 (upward), 22.2 (upward).

HRMS (ESI-Q/TOF MS) Calcd for $C_{14}H_{21}NO_6S_2$ [M+Na]⁺: 386.0708; found: 386.0714.



3-((4-Fluorobenzyl)amino)-2,2-dimethyl-3-oxopropyl methanesulfonate (2i)

Brown slurry (127 mg, 42%). $R_f = 0.50$, 60% EtOAc in n-hexane.


¹H NMR (400 MHz, CDCl₃) δ 7.25-7.21 (m, 2H), 7.04-6.99 (m, 2H), 6.12 (br s, 1H), 4.41 (d, J = 6.0 Hz, 2H), 4.21 (s, 2H), 2.93 (s, 3H), 1.28 (s, 6H).

¹³C NMR (100 MHz, CDCl₃) δ 174.3 (C=O), 162.2 (CF), 133.8 (C), 129.3 (CH), 115.6 (CH), 76.1 (CH₂), 43.1 (CH₂), 42.8 (C), 36.9 (CH₃), 22.2 (CH₃).

DEPT-135 (100 MHz, CDCl₃) δ 129.3 (upward), 115.6 (upward), 76.1 (downward), 43.1 (downward), 36.9 (upward), 22.2 (upward).

¹⁹F NMR (376 MHz, CDCl₃) δ -114.7.

HRMS (ESI-Q/TOF MS) Calcd for $C_{13}H_{18}FNO_4S$ [M+Na]⁺: 326.0838; found: 326.0840.



3-((4-Chlorobenzyl)amino)-2,2-dimethyl-3-oxopropyl methanesulfonate (2j)


Dark slurry (143 mg, 45%). $R_f = 0.60$, 50% EtOAc in n-hexane.

¹H NMR (400 MHz, CDCl₃) δ 7.34-7.32 (m, 2H), 7.23-7.21 (m, 2H), 6.16 (br s, 1H), 4.44 (d, *J* = 5.6 Hz, 2H), 4.24 (s, 2H), 2.95 (s, 3H), 1.31 (s, 6H).

¹³C NMR (100 MHz, CDCl₃) δ 174.4 (C=O), 133.6 (C), 133.4 (C), 128.9 (CH), 76.1 (CH₂), 43.1 (CH₂), 42.8 (C), 36.9 (CH₃), 22.2 (CH₃).

DEPT-135 (100 MHz, CDCl₃) δ 128.9 (upward), 76.1 (downward), 43.0 (downward), 36.9 (upward), 22.2 (upward).

HRMS (ESI-Q/TOF MS) Calcd for $C_{13}H_{18}CINO_4S$ [M+Na]⁺: 342.0543; found: 342.0546.



3-((4-Bromobenzyl)amino)-2,2-dimethyl-3-oxopropyl methanesulfonate (2k)

Light brown solid (182 mg, 50%). $R_f = 0.50$, 55% EtOAc in n-hexane.


Mp: 52-54 °C.

¹H NMR (400 MHz, CDCl₃) δ 7.45 (d, *J* = 8.0 Hz, 2H), 7.14 (d, *J* = 8.4 Hz, 2H), 6.30 (br s, 1H), 4.39 (d, *J* = 5.6 Hz, 2H), 4.21 (s, 2H), 2.94 (s, 3H), 1.28 (s, 6H).

¹³C NMR (100 MHz, CDCl₃) δ 174.4 (C=O), 137.2 (C), 131.8 (CH), 129.2 (CH), 121.4 (C), 76.1 (CH₂), 43.0 (CH₂), 42.7 (C), 36.9 (CH₃), 22.2 (CH₃).

DEPT-135 (100 MHz, CDCl₃) δ 131.9 (upward), 129.2 (upward), 76.1 (downward), 43.1 (downward), 36.9 (upward), 22.2 (upward).

HRMS (ESI-Q/TOF MS) Calcd for $C_{13}H_{18}BrNO_4S$ [M+Na]⁺: 386.0038; found: 386.0041.



3-((3,4-Dichlorobenzyl)amino)-2,2-dimethyl-3-oxopropyl methanesulfonate (2l)

Brown solid (194 mg, 55%). $R_f = 0.50$, 55% EtOAc in n-hexane.


Mp: 75-78 °C.

¹H NMR (400 MHz, CDCl₃) δ 7.41 (d, *J* = 8.0 Hz, 1H), 7.36 (d, *J* = 2.0 Hz, 1H), 7.11 (dd, *J* = 2.0, 8.0 Hz, 1H), 6.31 (br s, 1H), 4.41 (d, *J* = 6.0 Hz, 2H), 4.23 (s, 2H), 2.99 (s, 3H), 1.31 (s, 6H).

¹³C NMR (100 MHz, CDCl₃) δ 174.6 (C=O), 138.5 (C), 132.7 (C), 131.5 (C), 130.7 (CH), 129.4 (CH), 126.8 (CH), 76.0 (CH₂), 42.8 (C), 42.6 (CH₂), 37.0 (CH₃), 22.2 (CH₃).

DEPT-135 (100 MHz, CDCl₃) δ 130.7 (upward), 129.4 (upward), 126.8 (upward), 75.9 (downward), 42.6 (downward), 37.0 (upward), 22.2 (upward).

HRMS (ESI-Q/TOF MS) Calcd for $C_{13}H_{17}Cl_2NO_4S$ [M+Na]⁺: 376.0153; found: 376.0157.



3-(Butylamino)-2,2-dimethyl-3-oxopropyl methanesulfonate (2m)


Yellow oil (140 mg, 56%). $R_f = 0.55$, 50% EtOAc in n-hexane.

¹H NMR (400 MHz, CDCl₃) δ 6.21 (br s, 1H), 4.08 (s, 2H), 3.11-3.08 (m, 2H), 2.90 (s, 3H), 1.38-1.34 (m, 2H), 1.23-1.18 (m, 2H), 1.13 (s, 6H), 0.80-0.77 (m, 3H).

¹³C NMR (100 MHz, CDCl₃) δ 174.4 (C=O), 76.1 (CH₂), 42.5 (C), 39.4 (CH₂), 36.8 (CH₃), 31.3 (CH₂), 22.0 (CH₃), 19.8 (CH₂), 13.6 (CH₃).

DEPT-135 (100 MHz, CDCl₃) δ 76.1 (downward), 39.6 (downward), 36.9 (upward), 31.5 (downward), 22.2 (upward), 20.0 (downward), 13.7 (upward).

HRMS (ESI-Q/TOF MS) Calcd for $C_{13}H_{17}Cl_2NO_4S$ [M+H]⁺: 252.1270; found: 252.1283.



2,2-Dimethyl-3-oxo-3-(pentan-3-ylamino)propyl methanesulfonate (2n)

White solid (132 mg, 50%). $R_f = 0.55$, 50% EtOAc in n-hexane.

Mp: 70-72 °C.

¹H NMR (400 MHz, CDCl₃) δ 5.39 (br s, 1H), 4.23 (s, 2H), 3.84-3.78 (m, 1H), 3.02 (s, 3H), 1.63-1.56 (m, 4H), 1.30 (s, 6H), 0.92 (t, *J* = 7.6 Hz, 6H).

¹³C NMR (100 MHz, CDCl₃) δ 174.1 (C=O), 76.1 (CH₂), 52.3 (CH), 42.7 (C), 36.9 (CH₃), 27.5 (CH₂), 22.4 (CH₃), 10.2 (CH₃).

DEPT-135 (100 MHz, CDCl₃) δ 76.1 (downward), 52.2 (upward), 36.9 (upward), 27.5 (downward), 22.4 (upward), 10.2 (upward).

HRMS (ESI-Q/TOF MS) Calcd for $C_{11}H_{23}NO_4S$ [M+Na]⁺: 288.1245; found: 288.1238.

3-(*tert*-Butylamino)-2,2-dimethyl-3-oxopropyl methanesulfonate (20)

White solid (50 mg, 20%). $R_f = 0.45$, 50% EtOAc in n-hexane.


Mp: 42-44 °C.

¹H NMR (400 MHz, CDCl₃) δ 5.54 (br s, 1H), 4.16 (s, 2H), 2.99 (s, 3H), 1.34 (s, 9H), 1.22 (s, 6H).

¹³C NMR (100 MHz, CDCl₃) δ 173.6 (C=O), 76.4 (CH₂), 51.4 (C), 43.0 (C), 36.9 (CH₃), 28.6 (CH₃), 22.3 (CH₃).

DEPT-135 (100 MHz, CDCl₃) δ 76.4 (downward), 36.9 (upward), 28.6 (upward), 22. (upward).

HRMS (ESI-Q/TOF MS) Calcd for $C_{11}H_{23}NO_4S$ [M+Na]⁺: 288.1245; found: 288.1249.



3-(Cyclohexylamino)-2,2-dimethyl-3-oxopropyl methanesulfonate (2p)

White solid (116 mg, 42%). $R_f = 0.50$, 40% EtOAc in n-hexane.


Mp: 77-79 °C.

¹H NMR (400 MHz, CDCl₃) δ 5.59 (br s, 1H), 4.22 (s, 2H), 3.79-3.72 (m, 1H), 3.03 (s, 3H), 1.93-1.90 (m, 2H), 1.75-1.71 (m, 2H), 1.66-1.63 (m, 1H), 1.43-1.35 (m, 2H), 1.27 (s, 6H), 1.21-1.15 (m, 3H).

¹³C NMR (100 MHz, CDCl₃) δ 173.4 (C=O), 76.1 (CH₂), 48.5 (CH), 42.5 (C), 36.9 (CH₃), 32.9 (CH₂), 25.5 (CH₂), 24.8 (CH₂), 22.3 (CH₃).

DEPT-135 (100 MHz, CDCl₃) δ 76.2 (downward), 48.5 (upward), 36.9 (upward), 32.9 (downward), 25.5 (downward), 24.8 (downward), 22.3 (upward).

HRMS (ESI-Q/TOF MS) Calcd for $C_{12}H_{23}NO_4S$ [M+Na]⁺: 300.1245; found: 300.1238.



3-(Cyclopentylamino)-2,2-dimethyl-3-oxopropyl methanesulfonate (2q)

Gray solid (92 mg, 35%). $R_f = 0.55$, 50% EtOAc in n-hexane.

Mp: 68-71 °C.

¹H NMR (400 MHz, CDCl₃) δ 5.70 (br s, 1H), 4.20 (s, 2H), 4.19-4.12 (m, 1H), 3.02 (s, 3H), 2.05-1.96 (m, 2H), 1.71-1.58 (m, 2H), 1.41-1.32 (m, 2H), 1.25 (s, 6H).

¹³C NMR (100 MHz, CDCl₃) δ 173.9 (C=O), 76.2 (CH₂), 51.5 (CH), 42.5 (C), 36.9 (CH₃), 33.1 (CH₂), 23.8 (CH₂), 22.3 (CH₃).

DEPT-135 (100 MHz, CDCl₃) δ 76.2 (downward), 51.5 (upward), 36.9 (upward), 33.1 (downward), 23.8 (downward), 22.3 (upward).

HRMS (ESI-Q/TOF MS) Calcd for $C_{11}H_{21}NO_4S$ [M+Na]⁺: 286.1089; found: 286.1098.

3-(Cyclobutylamino)-2,2-dimethyl-3-oxopropyl methanesulfonate (2r)

Light yellow solid (22 mg, 42%). $R_f = 0.45$, 50% EtOAc in n-hexane.

Mp: 97-101 °C.

¹H NMR (400 MHz, CDCl₃) δ 5.83 (br s, 1H), 4.37-4.31 (m, 1H), 4.19 (s, 2H), 3.00 (s, 3H), 2.39-2.32 (m, 2H), 1.90-1.80 (m, 2H), 1.77-1.71 (m, 2H), 1.25 (s, 6H).

¹³C NMR (100 MHz, CDCl₃) δ 173.5 (C=O), 76.1 (CH₂), 45.0 (CH), 42.4 (C), 36.9 (CH₃), 31.0 (CH₂), 22.2 (CH₃), 15.1 (CH₂).

DEPT-135 (100 MHz, CDCl₃) δ 76.1 (downward), 45.0 (upward), 36.9 (upward), 31.1 (downward), 22.2 (upward), 15.1 (downward).

HRMS (ESI-Q/TOF MS) Calcd for $C_{10}H_{19}NO_4S$ [M+Na]⁺: 272.0932; found: 272.0928.

3-((2-Methoxyethyl)amino)-2,2-dimethyl-3-oxopropyl methanesulfonate (2s)


Light brown oil (106 mg, 42%). $R_f = 0.30$, 80% EtOAc in n-hexane.

¹H NMR (400 MHz, CDCl₃) δ 6.17 (br s, 1H), 4.22 (s, 2H), 3.48-3.43 (m, 2H), 3.37 (s, 3H), 3.02 (s, 3H), 1.28 (s, 6H).

¹³C NMR (100 MHz, CDCl₃) δ 174.4 (C=O), 76.0 (CH₂), 70.9 (CH₂), 58.9 (CH₃), 42.7 (C), 39.5 (CH₂), 36.9 (CH₃), 22.2 (CH₃).

DEPT-135 (100 MHz, CDCl₃) δ 76.0 (downward), 70.9 (downward), 58.8 (upward), 39.5 (downward), 36.9 (upward), 22.2 (upward).

HRMS (ESI-Q/TOF MS) Calcd for $C_9H_{19}NO_5S$ [M+Na]⁺: 276.0882; found: 276.0893.



2-Methyl-2-((4-nitrobenzyl)carbamoyl)butyl methanesulfonate (2t)


Dark slurry (200 mg, 58%). $R_f = 0.50$, 60% EtOAc in n-hexane.

¹H NMR (400 MHz, CDCl₃) δ 8.18 (d, *J* = 8.8 Hz, 2H), 7.44 (d, *J* = 8.8 Hz, 2H), 6.45 (br s, 1H), 4.63-4.52 (m, 2H), 4.41 (d, *J* = 9.2 Hz, 1H), 4.11 (d, *J* = 9.2 Hz, 1H), 2.98 (s, 3H), 1.81-1.72 (m, 1H), 1.57-1.48 (m, 1H), 1.33 (s, 3H), 0.92 (t, *J* = 7.6 Hz, 3H).

¹³C NMR (100 MHz, CDCl₃) δ 174.2 (C=O), 147.3 (C), 145.8 (C), 128.1 (CH), 123.9 (CH), 75.1 (CH₂), 46.7 (C), 43.0 (CH₂), 36.9 (CH₃), 28.7 (CH₂), 18.5 (CH₃), 8.4 (CH₃).

DEPT-135 (100 MHz, CDCl₃) δ 128.1 (upward), 123.9 (upward), 75.1 (downward), 43.0 (downward), 36.9 (upward), 28.7 (downward), 18.5 (upward), 8.4 (upward).

HRMS (ESI-Q/TOF MS) Calcd for $C_{14}H_{20}N_2O_6S$ [M+Na]⁺: 367.0940; found: 367.0941.



2-Methyl-2-((4-nitrobenzyl)carbamoyl)hexyl methanesulfonate (2u)

Brown solid (178 mg, 48%). $R_f = 0.50$, 50% EtOAc in n-hexane.


Mp: 89-92 °C.

¹H NMR (400 MHz, CDCl₃) δ 8.15 (d, *J* = 8.8 Hz, 2H), 7.43 (d, *J* = 8.8 Hz, 2H), 6.50 (br s, 1H), 4.62-4.39 (m, 2H), 4.40 (d, *J* = 9.2 Hz, 1H), 4.08 (d, *J* = 9.6 Hz, 1H), 2.97 (s, 3H), 1.71-1.63 (m, 1H), 1.48-1.40 (m, 1H), 1.33 (s, 3H), 1.31-1.25 (m, 3H), 1.21-1.16 (m, 1H), 0.88 (t, *J* = 6.8 Hz, 3H).

¹³C NMR (100 MHz, CDCl₃) δ 174.3 (C=O), 147.2 (C), 145.9 (C), 128.1 (CH), 123.9 (CH), 75.4 (CH₂), 46.3 (C), 43.0 (CH₂), 36.9 (CH₃), 35.7 (CH₂), 26.1 (CH₂), 23.0 (CH₂), 18.9 (CH₃), 13.9 (CH₃).

DEPT-135 (100 MHz, CDCl₃) δ 128.1 (upward), 123.9 (upward), 75.3 (downward), 43.0 (downward), 36.9 (upward), 35.7 (downward), 26.1 (downward), 23.0 (downward), 19.0 (upward), 13.9 (upward).

HRMS (ESI-Q/TOF MS) Calcd for $C_{16}H_{24}N_2O_6S$ [M+Na]⁺: 395.1253; found: 395.1246.



2-Methyl-3-((4-nitrobenzyl)amino)-3-oxopropyl methanesulfonate (2v)

Brown solid (25 mg, 8%). $R_f = 0.40$, 80% EtOAc in n-hexane.


Mp: 112-114 °C.

¹H NMR (400 MHz, CDCl₃) δ 8.19 (d, *J* = 8.4 Hz, 2H), 7.46 (d, *J* = 8.8 Hz, 2H), 6.45 (br s, 1H), 4.65-4.49 (m, 2H), 4.39-4.26 (m, 2H), 3.00 (s, 3H), 2.87-2.78 (m, 1H), 1.25 (d, *J* = 7.2 Hz, 3H).

¹³C NMR (100 MHz, CDCl₃) δ 173.0 (C=O), 147.3 (C), 145.6 (C), 128.1 (CH), 123.9 (CH), 71.5 (CH₂), 42.9 (CH₂), 41.1 (CH), 37.2 (CH₃), 13.9 (CH₃).

DEPT-135 (100 MHz, CDCl₃) δ 128.1 (upward), 123.9 (upward), 71.4 (downward), 42.9 (downward), 41.1 (upward), 37.2 (upward), 13.9 (upward).

HRMS (ESI-Q/TOF MS) Calcd for $C_{12}H_{16}N_2O_6S$ [M+Na]⁺: 339.0627; found: 339.0622.



3-((4-Nitrobenzyl)amino)-3-oxopropyl methanesulfonate (2w)

Light yellow solid (9 mg, 3%). $R_f = 0.25$, 80% EtOAc in n-hexane.


Mp: 109-112 °C.

¹H NMR (400 MHz, CDCl₃) δ 8.21 (d, *J* = 8.0 Hz, 2H), 7.47 (d, *J* = 8.4 Hz, 2H), 6.30 (br s, 1H), 4.60 (s, 2H), 4.58 (t, *J* = 6.4 Hz, 2H), 3.04 (s, 3H), 2.73 (t, *J* = 5.6 Hz, 2H).

¹³C NMR (100 MHz, CDCl₃) δ 169.0 (C=O), 147.4 (C), 145.4 (C), 128.2 (CH), 124.0 (CH), 66.2 (CH₂), 43.0 (CH₂), 37.3 (CH₃), 36.2 (CH₂).

DEPT-135 (100 MHz, CDCl₃) δ 128.2 (upward), 124.0 (upward), 66.1 (downward), 43.0 (downward), 37.3 (upward), 36.3 (downward).

HRMS (ESI-Q/TOF MS) Calcd for $C_{11}H_{14}N_2O_6S$ [M+Na]⁺: 325.0470; found: 325.0464.



2,2-Dimethyl-3-(neopentylamino)-3-oxopropyl methanesulfonate (2x)

White solid (156mg, 59%). $R_f = 0.60$, 50% EtOAc in n-hexane.

Mp: 60-62 °C.


¹H NMR (400 MHz, CDCl₃) δ 5.81 (br s, 1H), 4.24 (s, 2H), 3.11 (d, J = 6.4 Hz, 2H), 3.02 (s, 3H), 1.31 (s, 3H), 0.93 (s, 9H).

¹³C NMR (100 MHz, CDCl₃) δ 174.3 (C=O), 76.0 (CH₂), 50.5 (CH₂), 42.8 (C), 36.9 (CH₃), 32.0 (C), 27.1 (CH₃), 22.3 (CH₃).

DEPT-135 (100 MHz, CDCl₃) δ 76.1 (downward), 50.6 (downward), 36.9 (upward), 27.1 (upward), 22.4 (upward).

HRMS (ESI-Q/TOF MS) Calcd for $C_{11}H_{23}NO_4S$ [M+Na]⁺: 288.1245; found: 288.1249.

(3) β-Fluoramides



N-(4-Nitrobenzyl)-3-fluoro-2,2-dimethylpropanamide (3a)

Gray solid (165 mg, 65%). $R_f = 0.50$, 50% EtOAc in n-hexane.

Mp: 72-75 °C.


¹H NMR (400 MHz, CDCl₃) δ 8.16 (d, *J* = 8.8 Hz, 2H), 7.39 (d, *J* = 8.8 Hz, 2H), 6.43 (br s, 1H), 4.55 (d, *J* = 6.0 Hz, 2H), 4.41 (d, *J* = 47.6 Hz, 2H), 1.25 (s, 6H).

¹³C NMR (100 MHz, CDCl₃) δ 175.6 (C=O), 147.4 (C), 146.2 (C), 128.1 (CH), 124.1 (CH), 89.3 (CH₂), 43.1 (CH₂), 21.7 (CH₃), 21.6 (CH₃).

DEPT-135 (100 MHz, CDCl₃) δ 128.0 (upward), 124.0 (upward), 89.1 (downward), 42.9 (downward), 21.5 (upward), 21.4 (upward).

¹⁹F NMR (376 MHz, CDCl₃) δ -74.0.

HRMS (ESI-Q/TOF MS) Calcd for $C_{12}H_{15}FN_2O_3$ [M+Na]⁺: 277.0964; found: 277.0958.



N-(2-Nitrobenzyl)-3-fluoro-2,2-dimethylpropanamide (3b)

Brown oil (152 mg, 60%). $R_f = 0.50$, 50% EtOAc in n-hexane.


¹H NMR (400 MHz, CDCl₃) δ 8.08-8.06 (m, 1H), 7.65-7.63 (m, 2H), 7.50-7.47 (m, 1H), 6.76 (br s, 1H), 4.71 (d, J = 6.4 Hz, 2H), 4.38 (d, J = 47.6 Hz, 2H), 1.22 (d, J = 2.0 Hz, 6H).

¹³C NMR (100 MHz, CDCl₃) δ 175.3 (C=O), 148.4 (C), 134.1 (CH), 133.6 (C), 132.1 (CH), 128.7 (CH), 125.1 (CH), 89.0 (CH₂), 43.3 (C), 41.4 (CH₂), 21.4 (CH₃).

DEPT-135 (100 MHz, CDCl₃) δ 134.1 (upward), 132.1 (upward), 128.7 (upward), 125.1 (upward), 89.0 (downward), 41.4 (downward), 21.4 (upward).

¹⁹F NMR (376 MHz, CDCl₃) δ -74.1.

HRMS (ESI-Q/TOF MS) Calcd for $C_{12}H_{15}FN_2O_3$ [M+Na]⁺: 277.0964; found: 277.0968.



N-(3-Nitrobenzyl)-3-fluoro-2,2-dimethylpropanamide (3c)

Brown oil (172 mg, 68%). $R_f = 0.50$, 50% EtOAc in n-hexane.


¹H NMR (400 MHz, CDCl₃) δ 8.12 (d, *J* = 8.0 Hz, 1H), 8.11 (s, 1H), 7.61 (d, *J* = 7.6 Hz, 1H), 7.51 (t, *J* = 8.0 Hz, 1H), 6.39 (br s, 1H), 4.56 (d, *J* = 6.0 Hz, 2H), 4.42 (d, *J* = 47.6 Hz, 2H), 1.26 (s, 6H).

¹³C NMR (100 MHz, CDCl₃) δ 175.6 (C=O), 148.3 (C), 140.8 (C), 133.4 (CH), 129.6 (CH), 122.3 (CH), 121.9 (CH), 89.1 (CH₂), 43.3 (C), 42.7 (CH₂), 21.4 (CH₃).

DEPT-135 (100 MHz, CDCl₃) δ 133.5 (upward), 129.7 (upward), 122.4 (upward), 122.1 (upward), 89.1 (downward), 42.7 (downward), 21.5 (upward).

¹⁹F NMR (376 MHz, CDCl₃) δ -74.1.

HRMS (ESI-Q/TOF MS) Calcd for $C_{12}H_{15}FN_2O_3$ [M+Na]⁺: 277.0964; found: 277.0974.



3-Fluoro-2,2-dimethyl-*N*-(4-(trifluoromethyl)benzyl)propanamide (3d)

Light yellow oil. $R_f = 0.50$, 33% EtOAc in n-hexane.


¹H NMR (400 MHz, CDCl₃) δ 7.61 (d, *J* = 8.0 Hz, 2H), 7.39 (d, *J* = 8.0 Hz, 2H), 6.31 (br s, 1H), 4.55 (d, *J* = 5.6 Hz, 2H), 4.44 (d, *J* = 47.6 Hz, 2H), 1.28 (d, *J* = 1.6 Hz, 6H).

¹³C NMR (100 MHz, CDCl₃) δ 175.2 (C=O), 142.4 (C), 129.7 (C), 127.6 (CH), 125.7 (CH), 124.1 (CF₃), 89.2 (CH₂), 43.3 (C), 43.1 (CH₂), 21.5 (CH₃).

DEPT-135 (100 MHz, CDCl₃) δ 127.6 (upward), 125.7 (upward), 89.2 (downward), 43.1 (downward), 21.5 (upward).

¹⁹F NMR (376 MHz, CDCl₃) δ -62.5, -74.1.

HRMS (ESI-Q/TOF MS) Calcd for $C_{13}H_{15}F_4NO$ [M+Na]⁺: 300.0987; found: 300.0982.



3-Fluoro-2,2-dimethyl-N-(2-(trifluoromethyl)benzyl)propanamide (3e)

White solid. $R_f = 0.55$, 33% EtOAc in n-hexane.

Mp: 60-62 °C.


¹H NMR (400 MHz, CDCl₃) δ 7.67 (d, *J* = 8.0 Hz, 1H), 7.55-7.51 (m, 2H), 7.42-7.38 (m, 1H), 6.31 (br s, 1H), 4.66 (d, *J* = 6.0 Hz, 2H), 4.41 (d, *J* = 47.6 Hz, 2H), 1.24 (d, *J* = 2.0 Hz, 6H).

¹³C NMR (100 MHz, CDCl₃) δ 175.1 (C=O), 136.6 (C), 132.4 (CH), 130.4 (CH), 128.1 (C), 127.6 (CH), 126.0 (CH), 124.4 (CF₃), 89.1 (CH₂), 43.2 (C), 40.3 (CH₂), 21.4 (CH₃).

DEPT-135 (100 MHz, CDCl₃) δ 132.4 (upward), 130.4 (upward), 127.6 (upward), 126.0 (upward), 89.1 (downward), 40.3 (downward), 21.4 (upward).

¹⁹F NMR (376 MHz, CDCl₃) δ -59.6, -74.2.

HRMS (ESI-Q/TOF MS) Calcd for $C_{13}H_{15}F_4NO$ [M+Na]⁺: 300.0987; found: 300.0994.



3-Fluoro-2,2-dimethyl-N-(3-(trifluoromethyl)benzyl)propanamide (3f)

Yellow oil. $R_f = 0.50$, 33% EtOAc in n-hexane.


¹H NMR (400 MHz, CDCl₃) δ 7.56-7.52 (m, 2H), 7.48-7.47 (m, 2H), 6.31 (br s, 1H), 4.55 (d, J = 6.0 Hz, 2H), 4.44 (d, J = 47.6 Hz, 2H), 1.28 (d, J = 1.6 Hz, 6H).

¹³C NMR (100 MHz, CDCl₃) δ 175.2 (C=O), 139.4 (C), 130.9 (C), 130.8 (CH), 129.2 (CH), 124.3 (CH), 124.1 (CF₃), 89.1 (CH₂), 43.3 (C), 43.0 (CH₂), 21.5 (CH₃).

DEPT-135 (100 MHz, CDCl₃) δ 130.8 (upward), 129.2 (upward), 124.3 (upward), 89.1 (downward), 43.0 (downward), 21.5 (upward).

¹⁹F NMR (376 MHz, CDCl₃) δ -62.7, -74.1.

HRMS (ESI-Q/TOF MS) Calcd for $C_{13}H_{15}F_{4}NO$ [M+Na]⁺: 300.0987; found: 300.0981.



N-(4-Fluorobenzyl)-3-fluoro-2,2-dimethylpropanamide (3i)

Light brown oil. $R_f = 0.50$, 33% EtOAc in n-hexane.


¹H NMR (400 MHz, CDCl₃) δ 7.26-7.23 (m, 2H), 7.05-7.01 (m, 2H), 6.21 (br s, 1H), 4.44 (d, J = 5.6 Hz, 2H), 4.42 (d, J = 47.6 Hz, 2H), 1.26 (d, J = 1.6 Hz, 6H).

¹³C NMR (100 MHz, CDCl₃) δ 175.0 (C=O), 162.2 (CF), 134.1 (C), 129.2 (CH), 115.5 (CH), 89.2 (CH₂), 43.2 (C), 42.9 (CH₂), 21.5 (CH₃).

DEPT-135 (100 MHz, CDCl₃) δ 129.2 (upward), 115.5 (upward), 89.2 (downward), 42.9 (downward), 21.5 (upward).

¹⁹F NMR (376 MHz, CDCl₃) δ -74.1, -115.1.

HRMS (ESI-Q/TOF MS) Calcd for $C_{12}H_{15}F_2NO$ [M+Na]⁺: 250.1019; found: 250.1014.



N-(4-Chlorobenzyl)-3-fluoro-2,2-dimethylpropanamide (3j)

Light brown oil. $R_f = 0.50, 40\%$ EtOAc in n-hexane.


¹H NMR (400 MHz, CDCl₃) δ 7.33-7.31 (m, 2H), 7.22-7.20 (m, 2H), 6.22 (br s, 1H), 4.44 (d, J = 5.6 Hz, 2H), 4.42 (d, J = 47.6 Hz, 2H), 1.26 (d, J = 2.0 Hz, 6H).

¹³C NMR (100 MHz, CDCl₃) δ 175.1 (C=O), 136.9 (C), 133.3 (C), 128.8 (CH), 89.2 (CH₂), 43.2 (C), 42.9 (CH₂), 21.5 (CH₃).

DEPT-135 (100 MHz, CDCl₃) δ 128.9 (upward), 89.2 (downward), 42.9 (downward), 21.5 (upward).

¹⁹F NMR (376 MHz, CDCl₃) δ -74.1.

HRMS (ESI-Q/TOF MS) Calcd for $C_{12}H_{15}F_2NO$ [M+Na]⁺: 250.1019; found: 250.1014.



N-Butyl-3-fluoro-2,2-dimethylpropanamide (3m)

Colorless oil. $R_f = 0.70$, 40% EtOAc in n-hexane.


¹H NMR (400 MHz, CDCl₃) δ 5.87 (br s, 1H), 4.39 (d, *J* = 47.6 Hz, 2H), 3.30-3.25 (m, 2H), 1.53-1.47 (m, 2H), 1.39-1.33 (m, 2H), 1.22 (d, *J* = 1.6 Hz, 6H), 0.94 (t, *J* = 7.2 Hz, 3H).

¹³C NMR (100 MHz, CDCl₃) δ 175.0 (C=O), 89.2 (CH₂), 43.2 (C), 39.3 (CH₂), 31.5 (CH₂), 21.5 (CH₃), 20.0 (CH₂), 13.8 (CH₃).

DEPT-135 (100 MHz, CDCl₃) δ 89.2 (downward), 39.4 (downward), 31.6 (downward), 21.5 (upward), 20.0 (downward), 13.8 (upward).

¹⁹F NMR (376 MHz, CDCl₃) δ -74.1.

HRMS (ESI-Q/TOF MS) Calcd for C₉H₁₈FNO [M+Na]⁺: 198.1270; found: 198.1259.



3-Fluoro-2,2-dimethyl-N-(pentan-3-yl)propanamide (3n)

White solid. $R_f = 0.60$, 40% EtOAc in n-hexane.

Mp: 90-93 °C.


¹H NMR (400 MHz, CDCl₃) δ 5.54 (br s, 1H), 4.40 (d, *J* = 47.6 Hz, 2H), 3.86-3.79 (m, 1H), 1.63-1.52 (m, 2H), 1.43-1.32 (m, 2H), 1.24 (d, *J* = 2.0 Hz, 6H), 0.90 (t, *J* = 7.6 Hz, 6H).

¹³C NMR (100 MHz, CDCl₃) δ 174.8 (C=O), 89.3 (CH₂), 51.8 (CH), 43.2 (CH), 27.5 (CH₂), 21.7 (CH₃), 21.6 (CH₂), 10.2 (CH₃).

DEPT-135 (100 MHz, CDCl₃) δ 89.3 (downward), 51.8 (upward), 27.5 (downward), 21.7 (upward), 21.6 (downward), 10.2 (upward).

¹⁹F NMR (376 MHz, CDCl₃) δ -74.1.

HRMS (ESI-Q/TOF MS) Calcd for $C_{10}H_{20}FNO$ [M+Na]⁺: 212.1427; found: 212.1421.



N-Cyclohexyl-3-fluoro-2,2-dimethylpropanamide (3p)

White solid. $R_f = 0.70$, 40% EtOAc in n-hexane.

Mp: 88-91 °C.


¹H NMR (400 MHz, CDCl₃) δ 5.72 (br s, 1H), 4.38 (d, *J* = 47.6 Hz, 2H), 3.80-3.58 (m, 1H), 1.92-1.88 (m, 2H), 1.73-1.68 (m, 2H), 1.42-1.32 (m, 2H), 1.20 (d, 6H), 1.18-1.10 (m, 3H).

¹³C NMR (100 MHz, CDCl₃) δ 174.1 (C=O), 89.3 (CH₂), 48.1 (CH), 43.0 (C), 33.0 (CH₂), 25.6 (CH₂), 24.8 (CH₂), 21.6 (CH₃), 21.5 (CH₃).

DEPT-135 (100 MHz, CDCl₃) δ 89.3 (downward), 48.1 (upward), 33.0 (downward), 25.6 (downward), 24.8 (downward), 21.6 (upward), 21.5 (upward).

¹⁹F NMR (376 MHz, CDCl₃) δ -74.1.

HRMS (ESI-Q/TOF MS) Calcd for $C_{11}H_{20}FNO$ [M+Na]⁺: 224.1427; found: 224.1421.



N-Cyclopentyl-3-fluoro-2,2-dimethylpropanamide (3q)

White solid. $R_f = 0.60$, 40% EtOAc in n-hexane.

Mp: 97-100 °C.

¹H NMR (400 MHz, CDCl₃) δ 5.80 (br s, 1H), 4.38 (d, *J* = 47.6 Hz, 2H), 4.25-4.16 (m, 1H), 2.05-1.97 (m, 2H), 1.71-1.59 (m,4H), 1.41-1.33 (m, 2H), 1.21 (d, *J* = 1.6 Hz, 6H).


¹³C NMR (100 MHz, CDCl₃) δ 174.6 (C=O), 89.2 (CH₂), 51.2 (CH), 43.0 (C), 33.1 (CH₂), 23.8 (CH₂), 21.6 (CH₃), 21.5 (CH₃).

DEPT-135 (100 MHz, CDCl₃) δ 89.3 (downward), 51.2 (upward), 33.1 (downward), 23.8 (downward), 21.6 (upward), 21.5 (upward).

¹⁹F NMR (376 MHz, CDCl₃) δ -74.1.

HRMS (ESI-Q/TOF MS) Calcd for $C_{10}H_{18}FNO$ [M+Na]⁺: 210.1270; found: 210.1263.

(4) β -Lactams



3,3-Dimethyl-1-(4-nitrobenzyl)azetidin-2-one (4a)

Light yellow solid (150 mg, 64%). $R_f = 0.50$, 50% EtOAc in n-hexane.


Mp: 73-76 °C.

¹H NMR (400 MHz, CDCl₃) δ 8.22 (d, *J* = 8.8 Hz, 2H), 7.41 (d, *J* = 8.8 Hz, 2H), 4.47 (s, 2H), 2.99 (s, 2H), 1.32 (s, 6H).

¹³C NMR (100 MHz, CDCl₃) δ 174.1 (C=O), 147.5 (C), 143.5 (C), 128.7 (CH), 124.1 (CH), 54.3 (CH₂), 51.6 (C), 45.1 (CH₂), 21.2 (CH₃).

DEPT-135 (100 MHz, CDCl₃) δ 128.7 (upward), 124.1 (upward), 54.3 (downward), 45.1 (downward), 21.2 (upward).

HRMS (ESI-Q/TOF MS) Calcd for $C_{12}H_{14}N_2O_3$ [M+Na]⁺: 257.0902; found: 257.0893.



3,3-Dimethyl-1-(2-nitrobenzyl)azetidin-2-one (4b)

Brown oil (140 mg, 60%). $R_f = 0.50$, 50% EtOAc in n-hexane.

¹H NMR (400 MHz, CDCl₃) δ 8.06 (dd, J = 1.2, 8.0 Hz, 1H), 7.69-7.65 (m, 1H), 7.54-7.48 (m, 2H), 4.74 (s, 2H), 3.12 (s, 2H), 1.35 (s, 6H).

¹³C NMR (100 MHz, CDCl₃) δ 174.4 (C=O), 148.5 (C), 133.9 (CH), 131.8 (C), 130.7 (CH), 128.7 (CH), 125.1 (CH), 55.4 (CH₂), 51.4 (C), 42.8 (CH₂), 21.3 (CH₃).

DEPT-135 (100 MHz, CDCl₃) δ 133.9 (upward), 130.7 (upward), 128.7 (upward), 125.1 (upward), 55.4 (downward), 42.8 (downward), 21.3 (upward).

HRMS (ESI-Q/TOF MS) Calcd for $C_{12}H_{14}N_2O_3$ [M+Na]⁺: 257.0902; found: 257.0908.

 O_2N

3,3-Dimethyl-1-(3-nitrobenzyl)azetidin-2-one (4c)

Brown oil (164 mg, 67%). $R_f = 0.50$, 50% EtOAc in n-hexane.


¹H NMR (400 MHz, CDCl₃) δ 8.14 (d, J = 8.0 Hz, 1H), 8.07 (s, 1H), 7.60 (d, J = 7.6

Hz, 1H), 7.54 (t, *J* = 8.0 Hz, 1H), 4.47 (s, 2H), 3.01 (s, 2H), 1.31 (s, 6H).

¹³C NMR (100 MHz, CDCl₃) δ 174.1 (C=O), 148.5 (C), 138.3 (C), 134.0 (CH), 130.0 (CH), 122.7 (CH), 122.6 (CH), 54.2 (CH₂), 51.5 (C), 44.9 (CH₂), 21.2 (CH₃).

DEPT-135 (100 MHz, CDCl₃) δ 134.0 (upward), 130.0 (upward), 122.8 (upward), 122.7 (upward), 54.3 (downward), 44.9 (downward), 21.2 (upward).

HRMS (ESI-Q/TOF MS) Calcd for $C_{12}H_{14}N_2O_3$ [M+Na]⁺: 257.0902; found: 257.0902.



3,3-Dimethyl-1-(4-(trifluoromethyl)benzyl)azetidin-2-one (4d)

Brown oil. $R_f = 0.50$, 33% EtOAc in n-hexane.


¹H NMR (400 MHz, CDCl₃) δ 7.64 (d, *J* = 8.4 Hz, 2H), 7.38 (d, *J* = 8.0 Hz, 2H), 4.45 (s, 2H), 2.99 (s, 2H), 1.34 (s, 6H).

¹³C NMR (100 MHz, CDCl₃) δ 174.0 (C=O), 140.1 (C), 130.0 (C), 128.3 (CH), 125.8 (CH), 122.7 (CF₃), 54.0 (CH₂), 51.3 (C), 45.2 (CH₂), 21.2 (CH₃).

DEPT-135 (100 MHz, CDCl₃) δ 128.3 (upward), 125.8 (upward), 54.1 (downward), 45.2 (downward), 21.2 (upward).

¹⁹F NMR (376 MHz, CDCl₃) δ -62.6.

HRMS (ESI-Q/TOF MS) Calcd for $C_{13}H_{14}F_{3}NO$ [M+Na]⁺: 280.0925; found: 280.0929.



3,3-Dimethyl-1-(2-(trifluoromethyl)benzyl)azetidin-2-one (4e)

Colorless oil. $R_f = 0.55$, 33% EtOAc in n-hexane.


¹H NMR (400 MHz, CDCl₃) δ 7.68 (d, *J* = 8.0 Hz, 1H), 7.58 (t, *J* = 7.6 Hz, 1H), 7.49 (d, *J* = 6.07.6 Hz, 1H), 7.42 (t, *J* = 7.6 Hz, 1H), 4.58 (s, 2H), 2.98 (s, 2H), 1.32 (s, 6H).

¹³C NMR (100 MHz, CDCl₃) δ 174.2 (C=O), 134.8 (C), 132.5 (CH), 130.4 (CH), 128.5 (C), 127.7 (CH), 126.0 (CH), 124.2 (CF₃), 54.3 (CH₂), 51.1 (C), 41.9 (CH₂), 21.1 (CH₃).

DEPT-135 (100 MHz, CDCl₃) δ 132.4 (upward), 130.4 (upward), 127.7 (upward), 126.0 (upward), 54.3 (downward), 41.9 (downward), 21.1 (upward).

¹⁹F NMR (376 MHz, CDCl₃) δ -59.1.

HRMS (ESI-Q/TOF MS) Calcd for $C_{13}H_{14}F_3NO$ [M+Na]⁺: 280.0925; found: 280.0932.



3,3-Dimethyl-1-(3-(trifluoromethyl)benzyl)azetidin-2-one (4f)

Brown slurry. $R_f = 0.50$, 33% EtOAc in n-hexane.

¹H NMR (400 MHz, CDCl₃) δ 7.59 (d, J = 7.6 Hz, 1H), 7.53-7.45 (m, 3H), 4.45 (s, 2H), 2.99 (s, 2H), 1.34 (s, 6H).

¹³C NMR (100 MHz, CDCl₃) δ 174.1 (C=O), 137.1 (C), 131.3 (CH), 131.0 (C), 129.4 (CH), 124.6 (CH), 123.9 (CF₃), 54.0 (CH₂), 51.3 (C), 45.2 (CH₂), 21.2 (CH₃).

DEPT-135 (100 MHz, CDCl₃) δ 131.3 (upward), 129.4 (upward), 124.6 (upward), 54.0 (downward), 45.2 (downward), 21.2 (upward).

¹⁹F NMR (376 MHz, CDCl₃) δ -62.7.

HRMS (ESI-Q/TOF MS) Calcd for $C_{13}H_{14}F_3NO$ [M+Na]⁺: 280.0925; found: 280.0931.

1-(4-Fluorobenzyl)-3,3-dimethylazetidin-2-one (4i)

Brown oil. $R_f = 0.50$, 33% EtOAc in n-hexane.

¹H NMR (400 MHz, CDCl₃) δ 7.24-7.20 (m, 2H), 7.07-7.03 (t, *J* = 8.8 Hz, 2H), 4.35 (s, 2H), 2.94 (s, 2H), 1.31 (s, 6H).

¹³C NMR (100 MHz, CDCl₃) δ 173.9 (C=O), 162.3 (CF), 131.7 (C), 129.7 (CH), 115.7 (CH), 53.7 (CH₂), 51.0 (C), 44.9 (CH₂), 21.2 (CH₃).

DEPT-135 (100 MHz, CDCl₃) δ 129.7 (upward), 115.7 (upward), 53.7 (downward), 44.9 (downward), 21.2 (upward).

¹⁹F NMR (376 MHz, CDCl₃) δ -114.7.

HRMS (ESI-Q/TOF MS) Calcd for $C_{13}H_{17}Cl_2NO_4S$ [M+H]⁺: 208.1138; found: 208.1145.

1-(4-Chlorobenzyl)-3,3-dimethylazetidin-2-one (4j)


Brown oil. $R_f = 0.50$, 40% EtOAc in n-hexane.

¹H NMR (400 MHz, CDCl₃) δ 7.33 (d, *J* = 8.4 Hz, 2H), 7.18 (d, *J* = 8.4 Hz, 2H), 4.34 (s, 2H), 2.94 (s, 2H), 1.30 (s, 6H).

¹³C NMR (100 MHz, CDCl₃) δ 174.0 (C=O), 134.4 (C), 133.5 (C), 129.4 (CH), 129.0 (CH), 53.8 (CH₂), 51.1 (C), 45.0 (CH₂), 21.1 (CH₃).

DEPT-135 (100 MHz, CDCl₃) δ 129.4 (upward), 129.0 (upward), 53.8 (downward), 45.0 (downward), 21.2 (upward).

HRMS (ESI-Q/TOF MS) Calcd for $C_{12}H_{14}CINO$ [M+Na]⁺: 246.0662; found: 246.0658.



1-Butyl-3,3-dimethylazetidin-2-one (4m)


Colorless oil. $R_f = 0.70$, 20% EtOAc in n-hexane.

¹H NMR (400 MHz, CDCl₃) δ 4.13-4.06 (m, 1H), 3.02 (s, 2H), 1.86-1.82 (m, 2H), 1.71-1.59 (m, 6H), 1.29 (s, 6H).

¹³C NMR (100 MHz, CDCl₃) δ 173.9 (C=O), 54.1 (CH₂), 50.3 (C), 41.0 (CH), 29.7 (CH₂), 21.3 (CH₃), 20.1 (CH₂), 13.7 (CH₃).

DEPT-135 (100 MHz, CDCl₃) δ 54.2 (downward), 41.0 (downward), 29.7 (downward), 21.3 (upward), 20.1 (downward), 13.7 (upward).

HRMS (ESI-Q/TOF MS) Calcd for C₉H₁₇NO [M+Na]⁺: 178.1208; found: 178.1195.



3,3-Dimethyl-1-(pentan-3-yl)azetidin-2-one (4n)

Colorless oil. $R_f = 0.60$, 40% EtOAc in n-hexane.

¹H NMR (400 MHz, CDCl₃) δ 3.52-3.45 (m, 1H), 2.97 (s, 2H), 1.56-1.39 (m, 4H), 1.33 (s, 6H), 0.95 (t, *J* = 8.0 Hz, 6H).

¹³C NMR (100 MHz, CDCl₃) δ 174.6 (C=O), 54.1 (CH), 50.7 (CH₂), 49.2 (C), 25.8 (CH₂), 21.6 (CH₃), 11.0 (CH₃).

HRMS (ESI-Q/TOF MS) Calcd for C₁₀H₁₉NO [M+Na]⁺: 192.1364; found: 192.1360.

N T

1-Cyclohexyl-3,3-dimethylazetidin-2-one (4p)

Colorless oil. $R_f = 0.70, 40\%$ EtOAc in n-hexane.

¹H NMR (400 MHz, CDCl₃) δ 3.59-3.52 (m, 1H), 3.01 (s, 2H), 1.86-1.83 (m, 2H), 1.79-1.76 (m, 2H), 1.67-1.61 (m, 2H), 1.35-1.31 (m, 3H), 1.29 (s, 6H), 1.18-1.11 (m, 1H).

¹³C NMR (100 MHz, CDCl₃) δ 173.2 (C=O), 51.5 (CH₂), 50.1 (CH), 49.0 (CH), 30.7 (CH₂), 25.3 (CH₂), 24.9 (CH₂), 21.2 (CH₃).

DEPT-135 (100 MHz, CDCl₃) δ 51.5 (downward), 50.1 (upward), 30.7 (downward), 25.3 (downward), 24.9 (downward), 21.2 (upward).

HRMS (ESI-Q/TOF MS) Calcd for C₁₁H₁₉NO [M+Na]⁺: 204.1364; found: 204.1356.

1-Cyclopentyl-3,3-dimethylazetidin-2-one (4q)

Colorless oil. $R_f = 0.60$, 40% EtOAc in n-hexane.


¹H NMR (400 MHz, CDCl₃) δ 4.13-4.06 (m, 1H), 3.02 (s, 2H), 1.86-1.82 (m, 2H), 1.71-1.59 (m, 6H), 1.29 (s, 6H).

¹³C NMR (100 MHz, CDCl₃) δ 173.5 (C=O), 52.3 (CH₂), 52.0 (CH), 48.9 (C), 30.1 (CH₂), 24.1 (CH₂), 22.2 (CH₃).

DEPT-135 (100 MHz, CDCl₃) δ 52.3 (downward), 52.0 (upnward), 30.1 (downward), 24.1 (downward), 21.2 (upward).

HRMS (ESI-Q/TOF MS) Calcd for C₁₀H₁₇NO [M+Na]⁺: 190.1208; found: 190.1200.

(5) Other halogenated amides



3-Chloro-2,2-dimethyl-N-(4-nitrobenzyl)propanamide (5a)

White solid. $R_f = 0.55$, 50% EtOAc in n-hexane.

Mp: 79-83 °C.


¹H NMR (400 MHz, CDCl₃) δ 8.18 (d, *J* = 8.4 Hz, 2H), 7.45 (d, *J* = 8.4 Hz, 2H), 6.39 (br s, 1H), 4.58 (d, *J* = 6.0 Hz, 2H), 3.67 (s, 2H), 1.36 (s, 6H).

¹³C NMR (100 MHz, CDCl₃) δ 175.1 (C=O), 147.2 (C), 145.9 (C), 128.1 (CH), 123.9 (CH), 52.8 (CH₂), 44.4 (C), 43.0 (CH₂), 23.6 (CH₃).

DEPT-135 (100 MHz, CDCl₃) & 128.1 (upward), 123.9 (upward), 52.8 (downward),

43.0 (downward), 23.6 (upward).

HRMS (ESI-Q/TOF MS) Calcd for $C_{12}H_{15}ClN_2O_3$ [M+Na]⁺: 293.0669; found: 293.0682.



3-Bromo-2,2-dimethyl-*N***-(4-nitrobenzyl)propanamide (6a)**

White solid. $R_f = 0.55$, 50% EtOAc in n-hexane.


Mp: 88-90 °C.

¹H NMR (400 MHz, CDCl₃) δ 8.16 (d, *J* = 8.8 Hz, 2H), 7.46 (d, *J* = 8.8 Hz, 2H), 6.39 (br s, 1H), 4.57 (d, *J* = 6.4 Hz, 2H), 3.56 (s, 2H), 1.39 (s, 6H).

¹³C NMR (100 MHz, CDCl₃) δ 175.0 (C=O), 147.2 (C), 145.9 (C), 128.2 (CH), 123.8 (CH), 43.9 (C), 43.1 (CH₂), 42.3 (CH₂), 24.4 (CH₃).

DEPT-135 (100 MHz, CDCl₃) δ 128.2 (upward), 123.9 (upward), 43.1 (downward), 42.2 (downward), 24.4 (upward).

HRMS (ESI-Q/TOF MS) Calcd for $C_{12}H_{15}BrN_2O_3$ [M+Na]⁺: 337.0164; found: 337.0163.



3-Iodo-2,2-dimethyl-*N*-(4-nitrobenzyl)propanamide (7a)

White cystal. $R_f = 0.55$, 50% EtOAc in n-hexane.

Mp: 105-108 °C.

¹H NMR (400 MHz, CDCl₃) δ 8.17 (d, *J* = 8.8 Hz, 2H), 7.48 (d, *J* = 8.4 Hz, 2H), 6.20 (br s, 1H), 4.56 (d, *J* = 6.0 Hz, 2H), 3.39 (s, 2H), 1.40 (s, 6H).


¹³C NMR (100 MHz, CDCl₃) δ 175.1 (C=O), 147.5 (C), 145.9 (C), 128.6 (CH), 124.1 (CH), 43.4 (C), 43.3 (CH₂), 25.8 (CH₃), 17.7 (CH₂).


DEPT-135 (100 MHz, CDCl₃) δ 128.4 (upward), 123.9 (upward), 43.1 (downward), 25.6 (upward), 17.6 (downward).


HRMS (ESI-Q/TOF MS) Calcd for $C_{12}H_{15}IN_2O_3$ [M+Na]⁺: 385.0025; found: 385.0036.


2. NMR Spectra


(1) The amide substrates



























10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 -210 fl (zgm)








10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 -210 £1 (ppm)


































































































(2) β -Mesylated amides











$\begin{array}{c} 8.056\\ 7.636\\ 7.601\\ 7.601\\ 7.437\\ 7.437\\ 6.686\\ 6.686\\ 4.661\\ 4.666\\ 4.666\\ 4.666\\ 1.723\\ 1.753\\ 1.723\\ 1.$


-



























$\begin{array}{c} 7.535\\ 7.514\\ 7.470\\ 7.459\\ 6.420\\ 4.504\\ 4.490\\ 1.224\\ -2.936\end{array}$


-






























































$$-7.286$$


 -5.593
 -5.593
 -5.593
 3.723
 3.723
 3.027
 1.925
 1.925
 1.0125
 1.657
 1.657
 1.657
 1.657
 1.657
 1.657
 1.657
 1.657
 1.657
 1.657
 1.657
 1.657
 1.657
 1.657
 1.657
 1.657
 1.657
 1.657
 1.657
 1.657
 1.657
 1.657
 1.657
 1.657
 1.657
 1.657
 1.657
 1.657
 1.657
 1.657
 1.657
 1.657
 1.657
 1.657
 1.657
 1.657
 1.657
 1.657
 1.657
 1.657
 1.657
 1.657
 1.657
 1.657
 1.756
 1.756
 1.756
 1.756
 1.756
 1.756
 1.756
 1.7657
 1.7657
 1.1657
 1.1657
 1.1657
 1.1657
 1.1657
 1.1657
 1.1657
 1.1657
 1.1657
 1.1657
 1.1657
 1.1657
 1.1657
 1.1657
 1.1657
 1.1657
 1.1657
 1.1657
 1.1657
 1.1657
 1.1657
 1.1657
 1.1657
 1.1657
 1.1657
 1.1657
 1.1657
 1.1657
 1.1657
 1.1657
 1.1657
 1.1657
 1.1657
 1.1657
 1.1657
 1.1657
 1.1657
 1.1657
 1.1657
 1.1657
 1.1657
 1.1657
 1.1657
 1.1657
 1.1657
 1.1657
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1267
 1.1



















$$\begin{array}{c} -7.284 \\ -6.171 \\ -6.171 \\ 14.217 \\ 3.477 \\ 3.477 \\ 3.477 \\ 3.477 \\ 3.455 \\ 3.477 \\ 3.477 \\ 3.074 \\ 3.023 \\ 3.023 \\ 3.023 \\ 0.066 \end{array}$$































2w, DEPT 135




$$-5.809$$


 -4.192
 3.066
 3.050
 2.975
 -1.264
 -0.888







(3) β -Fluoramides












$\begin{array}{c} 8.086\\ 7.675\\ 7.675\\ 7.659\\ 7.636\\ 7.636\\ 7.504\\ 7.504\\ 7.504\\ 7.285\\ 7.$







--74.06




3b,¹⁹F NMR













__,__.










3d, ¹H NMR










$\begin{array}{c} 7.680\\ 7.546\\ 7.546\\ 7.515\\ 7.515\\ 7.515\\ 7.515\\ 7.515\\ 7.515\\ 7.515\\ 7.515\\ 7.515\\ 7.7383\\ 7.7383\\ 7.7383\\ 7.7383\\ 7.7383\\ 7.7383\\ 7.7384\\ 6.309\\ 6.309\\ 6.309\\ 1.712\\ 1.712\\ 1.244\\ 1.233\\ 1.$








10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 -210 fl (ppm)























3i, ¹⁹F NMR





10 0 –10 –20 –30 –40 –50 –60 –70 –80 –90 –100 –110 –120 –130 –140 –150 –160 –170 –180 –190 –200 –210 fl (рудн)













































-7.2845.644 4.930 4.401 4.401 4.282 4.175 4.079 4.079 3.145 7.1.996 1.996 1.934 1.934 1.934 1.934 1.934 1.936 1.936 1.1332 1.137 1.137 1.1372 1.1
















(4) β -Lactams










































10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 -210 Al (ppm) 7.285 7.240 7.227 7.218 7.076 7.055 7.032 -4.953 -4.953 -4.354 -4.354 -2.945 -0.088



16

15


14

13

12

'n

10 ģ



։ ք1 (բջամ)

5

4

ź

i


8


-3


-2

ò


-1










S-181






S-183








$$-7.284$$

 -7.284
 -7.284
 -7.284
 -7.2940
 -7.2997
 -7.2997
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772
 -1.772









(5) Other halogenated amides

